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METAL ORGANIC FRAMEWORKS AS HETEROGENEOUS NITRIC OXIDE CATALYSTS FOR 
USE IN THE DEVELOPMENT OF THERAPEUTIC POLYMER MATERIALS  
 
 
Implantable polymeric medical devices are subject to surface biofouling due to the deposition of 
microbial agents and the accumulation of proteins at the material interface. Consequently, medical 
devices which are intended for beneficial functions can become a potentially fatal threat. As a result 
biofouling resistant materials are vigorously sought through the manipulation of material surface 
properties and by eluting therapeutics on the material surface. Nitric oxide (NO) is a bioactive agent 
generated by most nucleated cells in the human body and is known to mediate antimicrobial and 
antithrombus effects while maintain the capacity to promote the proliferation of healthy tissues. As such, 
the development of NO releasing biomaterials is known to reduce incidences of surface biofouling. 
However, current NO releasing materials are limited to short lifetimes of used based on limited capacity 
of exogenous NO which can be incorporated into the material. In order to circumvent this problem the 
goal of this research is to develop a biomaterial which generates NO from an endogenously supplied 
source.   
Metal organic frameworks (MOFs) were selected for investigation as heterogeneous catalysts for the 
generation of NO from bioavailable NO donors, S-nitrosothiols (RSNOS). MOFs were evaluated as NO 
catalysts based on their capacity to react with various RSNO substrates and their maintained structural 
integrity under reaction conditions. Presented herein is the successful demonstration of a Cu-MOF for the 
catalytic generation of NO from bioavailable RSNOs donors. However, the limited stability of this proof 
of principle MOF in aqueous solution prompted the development of a MOF-NO catalyst that is suitable 
for physiological applications through tuning the organic ligands used in the construction of the 
framework. Finally a two-fold demonstration of the feasibility towards designing composite MOF based 
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biomaterials is presented as blended materials prepared via commercial manufacturing processes and via 
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Research Problem: Implantable polymeric medical devices are subject to surface biofouling due to the 
deposition of microbial agents and the accumulation of proteins at the material interface. Consequently, 
medical devices which are intended for beneficial functions can become a potentially fatal threat. As a 
result biofouling resistant materials are vigorously sought through the manipulation of material surface 
properties and by eluting therapeutics on the material surface. These approaches are currently met with 
only limited success due each approaches inherent limitation of counting either infectious microbes or the 
adhesion of thrombus forming biomolecules to the material surface.       
Research Goal: The development of a biomaterial which generates the bioactive agent nitric oxide from 
an endogenous source to counter the negative effects of surface biofouling via integration of the device 
into the host environment.  
Research Hypothesis: Nitric oxide is a bioactive agent generated by most nucleated cells in the human 
body known to mediate antimicrobial effects and promote the proliferation of healthy tissues. Therefore 
the development of an NO releasing material which can sustain the generation of physiologically relevant 
levels of NO by relying on endogenous supplies of NO over the device lifetime will result in the 
development of an antifouling material surface with potentially regenerative effects.     
Research Approach:  
1) In chapter 2 a method for the accurate quantification and reporting of bioavailable NO generated 
from NO donors in cell media solutions used for in vitro studies is presented. This work aims to 
! 2!
identify possible sources of discrepancies in the literature used to report therapeutic levels of NO 
by identifying riboflavin as an effective NO scavenging agent found as an additive in cell media 
solutions. Once established the method developed here was applied to a collaborative effort with 
the Vigh group in the neuroscience department at Colorado State University to measure the 
therapeutic dosage of NO needed to stimulate diseased retinal cells. These findings are not 
reported in the text, but the full manuscript is available in the appendix. 
$ Harding, J. L.; Reynolds, M. M. Analytical Chemistry 2014, 86, 2025. 
 
2) Chapter 3 discusses the use of a metal organic framework (MOF) for the catalytic generation of 
NO from bioavailable small molecule NO donors, S-nitrosothiols (RSNO). In this work the well 
studied Cu-MOF, CuBTC, was shown to catalytically generate NO.  The reactivity of the catalyst 
was determined based upon the rate of NO generation with each of the investigated RSNO 
substrates and was found to be influenced based on substrate size and polarity of terminal 
functional groups. The MOF catalyst remained intact following reaction with the RSNOs, but 
only when a non aqueous solvent, ethanol, was used.  Further exploration into the importance of 
the metal ion active site was shown using iron and aluminum based MOFs.     
$ Harding, J. L.; Reynolds, M. M. Journal of the American Chemical Society 2012, 
134, 3330. 
3) Presented in chapter 4 is the development of a MOF NO catalyst with structural stability in 
biological fluids.  In this work triazolae based ligand is coordinated to Cu2+ metal centers 
resulting in the formation of a robust framework towards aqueous environments. This material is 
shown to resist degradation even when exposed to biological fluids and maintains its activity as 
an NO catalyst.    
$ Harding, J.L.; Metz, J.M.; and Reynolds, M.M. Advanced Functional Materials 
2014, DOI:10.1002/adfm.201402529    
4) Chapter 5 outlines the feasibility of incorporating MOF NO catalysts into the polymeric matrix of 
existing medical devices utilizing commercial extrusion processes. In order to successfully 
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implement MOFs for use in therapeutic materials it is essential that existing manufacturing 
processes not require substantial modification. Furthermore, MOFs must retain their structural 
and chemical properties once incorporated into a device. As a result MOF-poly materials 
prepared according to commercial manufacturing methods were evaluated based on the structural 
integrity and reactivity of the material towards NO generation. Mechanical properties of the 
prepared material were not assessed.    
$ Harding, J. L.; Reynolds, M. M. Journal of Materials Chemistry B 2014, 2, 2530. 
5) In chapter 6 a method for the deposition of MOF crystals on the surface of flexible polymeric 
substrates is presented. The uniform deposition of MOF thin films on surfaces to form composite 
materials for use as membranes or supported heterogeneous catalysts is highly desirable, however 
many current approaches rely on the use of rigid inorganic substrates that are impractical for 
many real world applications. Instead this work presents a facile room temperature synthesis of 
covalently attached MOF crystals on the surface of a flexible organic substrates. This method 
results in the growth of crystals with uniform size and excellent surface coverage on the substrate 
that is indifferent to substrate size, topology, and topography making it an excellent method for 
incorporating MOF particles onto the surface of prefabricated materials.       
$ Manuscript in preparation 
Research Conclusions: This research represents a complete body of work from the development of an 
analytical method for evaluating the behavior of MOF NO catalysts to their ultimate incorporation into 
functional devices intended for biological applications. 
Project Background 
Medical Device Biofouling. Medical devices are a major component in the healthcare industry ranging 
from simple yet useful devices (Class I) such as tongue depressors and bandages to life-saving treatment 
options (Class III) including pacemakers and vascular stents.1 While Class I materials are generally 
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representative of a benign classification that pose little risk to patients, the Class III materials are 
considered high risk and are susceptible to resulting in adverse effects including patient injury or 
infection.2 Implantable devices are subject to the deposition of microbial agents on the material surface 
and the foreign body response which results in the accumulation of proteins and microbes on the surface 
of the device shown in Figure 1, posing a high risk for device impairment.3-5 Furthermore, the increasing 
use of invasive medical procedures for the implantation of devices leads to an increased risk for the 
development of device associated infections. Current estimates place the occurrence of nosocomial 
bacterial related infections at 65% and are associated with the growth of bacterial biofilms on device 
surfaces. 6 Severe biofouling of medical devices, ultimately resulting in device failure can only be 
corrected by the removal and replacement of the device through costly invasive procedures. Given the 
broad scope of medical devices in use and the complexity of physiological environments to which they 
are exposed makes the design of antifouling materials a challenge requiring multiple avenues of 
approach.4  
 
Figure 1. Deposition of microbial or protein based biofouling agents on the surface of a medical device 
ultimately resulting in device surface biofouling.   
While, the exact mechanisms of attachment of bioagents to the surface of medical devices is not well 
understood, physical and chemical surface properties are known to influence the type and extent of 
surface fouling 7. Upon insertion into a liquid environment a conditioning layer immediately forms 
composed of lipids and glycoproteins onto the device surface.2,7-9 The composition of the conditioning 
layer is dictated by the device surface properties, including charge and hydrophillicity, and environmental 
factors such as pH and temperature. The composition of the conditioning layer subsequently influences 
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what types of bacteria strains can colonize on the surface and the likelihood of thrombus formation which 
is the aggregation of proteins and platelets on a surface that results in the formation of a blood clot 7,10. 
Once a suitable environment for attachment is established bacterial species are capable of adhering to the 
surface and proliferating into microcolonies eventually forming biofilms. Biofilms found on blood 
contacting devices often include a large portion of host clotting proteins and immune cells intended to 
isolate the infection and prevent the formation of sepsis 10,11.  
Biocompatibility of materials is a defining condition for the use of any synthetic material for a biological 
application. However, the term biocompatibility is a bit ambiguous and is most commonly used in 
reference to the toxicity associated with the material and the likelihood of an adverse effect resulting from 
use of the material. In consideration of the current limitations of existing implantable devices with regards 
to their susceptibility towards biofouling, current medical device technology does not represent a truly 
biocompatible system. Instead the  design materials therefore must go beyond function by also 
considering the feasibility of the device intergrating with the host environment by countering the negative 
effects associated with surface biofouling 12 and ultimately facilitate the restoration of physiological 
function.   
Maintaining medical devices in a homeostatic environment with the biological interface is key for their 
sustained usage. The design of next generation biomedical devices is aimed at preventing surface fouling 
through passive and active approaches by the manipulation of physical and chemical surface properties to 
create anti-adhesive materials based on their ability to prevent the adhesion of noxious biomolecules 
(Figure2a-c) or antimicrobial by denaturing infectious microbes and subsequently restricting the 
proliferation of biofilms (Figure 2d-e). 13-21 While each approach is effective for the intended application 
the combined activity of anti-adhesive and antimicrobial functionalities into a single material would 
ultimately enhance the antifouling properties of medical devices 22,23 and with careful tuning may even 
facilitate the materials integration with the host environment. 
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Figure 2. Strategies in device design for antifouling polymeric surfaces a) anti-adhesive hydrophilic 
materials b)anti-adhesive hydrophobic materials c) anti-adhesive zwitterionic surface functionalization d) 
antimicrobial cationic surfaces e) antimicrobial or anti-adhesive biomolecule coated surfaces f) 
therapeutic drug eluting surfaces   
Development of Bioinspired Materials. The foreign body response is associated with the most adverse 
fouling effects, as result the functionalization of material surfaces with biomolecules is an advantageous 
approach for cloaking implanted medical devices. The controlled deposition of biomolecules on the 
surface of the device can create a physical and chemical barrier between fouling agents and the device 
surface without impairing the functionality of the device.24 Deposition of surfaces with biomolecules such 
as peptides offers the advantage of being inherently biocompatible and the associated cationic charge 
imparts antimicrobial activity. 25-28 The use of antimicrobial peptides peptides is effective against a broad 
range of microbes including pathogenic bacterial strains of Pseudomonas aeruginosa, Staphylococcus 
aureus, Streptococcus gordonii, Fusobacterium nucleatum and Porphyromonas gingivalis. 25 However, 
the antimicrobial activity of biomolecule peptides is closely associated with the identity of the peptide in 
use and furthermore peptide functionalization of surfaces do no prevent the deposition of fouling agents. 
Instead a biomolecule with multiple modes of action that can be continuously expressed on the material 
surface is quintessential.  
The most ubiquitous of all biomolecules, nitric oxide (NO) is generated as a part of the healthy function 
of most nucleated cells in the human body and is responsible for cellular signaling process in the 
cardiovascular, immune, and nervous systems. 29-34 Biosynthesis of NO is a result of the reaction of L-
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arginine with nitric oxide synthase (NOS), of which there are three: endothelial (eNOS), nervous (nNOS), 
and immune (iNOS). 35-37 As shown in Figure 3, the effect of NO is concentration dependent ranging from 
proliferative and protective effects at low concentration (1-30nM) to cytotoxic at higher concentrations 
(≥100nM).38 Both eNOS and nNOS maintain a low output of NO on cellular surfaces as normal 
physiological function in healthy hosts and a deficiency in NO is closely associated with the formation of 
arterial thrombus 39-41. However, iNOS is associated with immune responses and is the only NOS enzyme 
in which NO generation can be induced as result of inflammation or infection 42,43. As such, the levels of 
NO generated by iNOS are high and aimed at creating cytotoxic and biocidal effects. Macrophages are 
the primary sources of NO generated during immune responses and the subsequent antimicrobial action of 
NO is thought to occur via the mutation of microbial DNA, inhibition of DNA repair and synthesis in the 
microbe, and neutralization by peroxynitrite 43. As a result the development of NO releasing biomaterials 
offers the combined advantages of drug eluting materials with biomolecule functionalization to create a 
biomimetic surface.  
 
Figure 3. Role of NO in regulating a homeostatic environment and generating an immune response   
 
 
Classical Design of NO Biomaterials. As a biomolecule capable of antimicrobial, thrombolytic, and 
proliferative effects NO releasing materials are the subject of extensive investigations for combating 
medical device fouling and promoting device integration with the biological environment. Rather than 
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relying on enzymatic pathways for NO generation, small molecule NO donors, such as 
diazeniumdiolates44-47 or S-nitrosothiols48,49 (Figure 4), can be incorporated directly into polymeric 
matrices of existing devices as blended materials or covalently adhered to the surface.50 The release of 
NO from donor molecules is triggered in physiological conditions by pH and a temperature driven 
pathways for diazeniumdiolates (Figure 4a) and heat, light, and in the presence of catalytic Cu2+ ions for 
RSNOs (Figure 4b).  The release of NO from the donors incorporated into biomaterials results in site 
localized effect where the amount of NO generated is easily tuned based on the composition of the donor 
molecule. The use of NO donors are advantageous for tuning the dosage of NO delivered from a material 
due to the variable half-lives exhibited between 1 second and 24 hours.45,51 The incorporation of NO 
releasing groups into medical devices is established as effective for the prevention of thrombus and 
biofilm formation on 19,52-55. However, the shortcoming of current design properties however is the limited 
supply of NO that can be incorporated into the polymeric matrices, which ultimately limits the materials 
therapeutic lifetime of use.  
 
Figure 4. Small molecule NO donors and corresponding NO release pathways (a) S-nitrosothiols (RSNO) 
and (b) Diazeniumdiolates  
"!
Designing a Catalytic NO Material. An ideal NO material will maintain a continuous supply for the 
duration of the device lifetime or until the successful integration of the device within the physiological 
environment is achieved. Towards this end it is necessary to reimagine our approach to the development 
of NO materials, where rather than relying on incorporated reservoirs of NO we instead access the 
supplies of NO that are naturally being generated. Due to the rapid reactivity of NO (t1/2 = <1ms) the body 
has devised transport mechanisms of NO through the blood stream in the form of S-nitrosothiols present 
as both small molecule and protein pound derivatives of the amino acid L-cysteine.49,56 Therefore, as 
shown in Figure 5 the development of NO materials with long term NO release properties will capitalize
on the potential for the catalytic generation of NO from endogenous RSNOs through the incorporation of 
Cu2+ catalysts within the polymeric matrix of devices.    
 
Figure 5. Incorporation of a Cu-catalyst into the matrix of a polymeric material for the sustained 
generation of NO from bioavailable RSNO substrates   
Copper is an essential trace element found exclusively in protein bound configurations as enzymatic 
active sites.57 Notably protein bound Cu2+ ions are capable of reacting with bioavailable RSNOs resulting 
in the generation of NO. Subsequently, exploration of macromolecular Cu2+ complexes embedded into the 
matrix of polymeric materials via covalent attachment to the polymeric backbone or as blended 
materials.58-61 In each case the generation of NO from bioavailable RSNOs was demonstrated, however
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rapid leaching of the Cu-active site was observed resulting in deactivation of the material.  As such, based 
on the current state of research in the field of catalytic NO materials it is essential to progress towards the 
development of robust Cu catalyst that can withstand the physiological environment while maintaining its 
capacity to catalytically generate NO from endogenous RSNOs. 
Porous Solid State NO Catalysts. Porous solid state materials including zeolites and metal organic 
frameworks (MOFs)62-66 have drawn interest for use as NO materials due to their robust architectures and 
wide applicability. In particular MOFs have garnered increased interest in recent years with an excess of a 
4000 publications in 2013 alone.  The abundance of structurally distinct frameworks is a result of the 
versatile combinations of organic ligands and the metals selected for the synthesis. As such, MOFs have 
found applicability in a wide range of applications from gas storage to catalysis as a result of the robust 
3D crystalline networks that exhibit permanent porosity with tunable pore size and the reversible 
adsorption of substrates.  
The variable chemical and physical properties of MOFs make them promising platforms for biomedical 
applications due to their potential design for biodegradability, and tunability for a wide range of 
applications.64,67-70 Towards this end the large pore volumes of MOFs have made them attractive 
candidates for use as drug delivery vehicles.68,71 In particular the precedent for gas storage applications of 
MOFs has led to explorations of MOFs as NO delivery vehicles.64,72-74 As NO materials, MOFs can be 
loaded with NO as a physisorbed guest or through post synthetic modification of the framework for 
functionalization with covalently attached diazeniumdiolate NO donors. The use of MOFs as NO 
materials presents the highest loading capacity of any NO material to date, however a lack of capacity for 
tuning NO release kinetics and the finite supply of NO within the material ultimately limits the 
applicability.   
The exploration of MOFs as NO catalysts which rely on an endogenous sources of NO has the potential 
to impart long lasting delivery of NO and tunable NO generation kinetics. There are three approaches for 
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using MOFs as catalysts: First, active sites are located as a function of the metal ligand coordination 
cluster which forms the secondary building unit. Secondly, macrocyclic ligands such as porphyrin 
incorporated as a component of the MOF ligand subsequently bind a metal ion such as Zn, Fe, Mn, and 
Cu to create a bioinspired catalytic framework. Third, post synthetic modification of the MOF to 
incorporate catalytic species into the network either by covalently modifying the organic ligand or 
encapsulation of the active species within the MOF pore space. In this work I will focus on the use of the 
a Cu-based coordination cluster as the active site for reaction with RSNOs, described in Figure 6. 
 
Figure 6. RSNO NO donor substrates reacting with coordinatively unsaturated Cu active sites 
incorporated as the framework secondary building unit. 
Frameworks designed to utilize the metal coordination cluster as the active metal site must allow for the 
coordination of the substrate without incurring structural damage. Towards this end coordinatively 
unsaturated MOFs have successfully catalyzed numerous organic transformation reactions and are even 
successful for generating enantioselctive products.75,76 The development of MOF-NO catalysts therefore 
necessitates the use of a framework with coordinatively unsaturated Cu2+ metal centers in order to 
facilitate the adsorption of RSNO species. In addition, the porosity of the framework is essential for 
permitting the substrates access towards the catalytic centers and has the secondary advantage of 
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imparting substrate selectivity into the material. Most importantly however for the sustained use of the 
material as a BioMOF catalyst the framework must remain robust within the physiological environment.   
While extremely promising materials for an extensive range of applications, the use of MOFs as 
functional materials requires that the fine particles be incorporated into a secondary support. 77 Towards 
this end MOF composite materials have been explored in membrane science for chemical separations or 
sensing and even as heterogeneous catalysts. The key requirement for the preparation of MOF composite 
materials is after fabrication of the material it is essential that the MOF remains structurally and 
chemically unaffected without compromising functionality. The formation of a composite material can 
proceed via two routes 1) incorporating MOF particles directly into the matrix of a secondary support as a 
blend, or 2) chemical attachment of MOFs to the surface of substrates via in situ growth.78 MOF particles 
dispersed throughout a polymeric matrix impart a high degree of versatility towards the types of 
applications that the materials can be used for due to the flexibility of the support substrate. However, the 
limitation with this approach is the lack of uniformity in the layer of MOF crystals. Advantageously, the 
direct growth of MOFs onto surfaces results in the controlled deposition of uniform MOF thin film 
coatings with control over the thickness of the deposited layer, orientation of the crystal face, and even 
patterned surface deposition.79,80 However, the formation of MOF thin films onto substrate surfaces is 
primarily reported for rigid inorganic surfaces rather than flexible organic materials. This work will 
explore the development of MOF composite materials using both approaches. 
Research Summary. The primary goal of this research is to develop catalytic NO materials which utilize 
bioavailable RSNO substrates to generate nonfouling implantable medical devices.  A crucial step for the 
development of NO materials is the ability to accurately quantify NO. In this work the author explores the 
use of chemiluminescence based NO analysis for the accurate quantification of NO generated in cell 
media solutions to mimic in vitro studies and present a case study for the applicability of designing NO 
materials (Chapter 2). Presented next is the successful demonstration of a Cu-MOFs for the catalytic 
generation of NO from bioavailable RSNOs donors (Chapter 3). However the limited stability of this 
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proof of principle MOF in aqueous solution prompted the development of a MOF-NO catalyst that is 
suitable for physiological applications through tuning the organic ligands used in the construction of the 
framework (Chapter 4). Finally a two-fold demonstration of the feasibility towards designing composite 
MOF based biomaterials is presented as blended materials prepared via commercial manufacturing 
processes (Chapter 5) and via surface growth of MOFs on flexible polymeric substrates. This research 
represents a complete body of work from the development of an analytical method for evaluating the 
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Nitric oxide (NO) is an essential messenger in human physiology, mediating cellular processes ranging 
from proliferation to apoptosis.1-5 The effects of NO are concentration dependent and control over the 
instantaneous amount of NO available to cells is essential for determining the therapeutic NO dosages for 
various applications.  As such, the development of NO therapeutic materials relies on accurate 
quantitative NO measurements that provide both total NO release from the NO donor as well as 
instantaneous NO concentrations.6  Based on the complexity of the cell media environment, inaccurate 
NO reporting often occurs for in vitro studies.7 These inaccuracies result from using inert media such as 
phosphate buffer saline (PBS), failing to account for the reactivity of media components.  In this work, 
we describe a method for directly quantifying the instantaneous and total amounts of NO from commonly 
used NO donors in commercially available cell media routinely used for endothelial and neural cell lines.  
A riboflavin-tryptophan complex found in the media was identified as the major scavenger of NO in the 
cell media and likely reacts with NO via a radical-radical reaction.  This finding significantly impacts the 
amount of available NO.  The scavenging effects are concentration dependent on the riboflavin-
tryptophan complex and the NO release rate from the NO donor. The results of this study provide insights 
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on the exogenous amounts of NO that are present in cell media and may provide an explanation for 
differences in NO dosages between buffer experiments and in vitro and in vivo studies. 
Introduction 
The history of nitric oxide as a therapeutic can be traced back over one hundred years in the form of 
physicians prescribing nitroglycerin for treating angina.8,9 Yet it wasn’t until the discovery of NO as the 
endothelial relaxation factor responsible for vasodilation of blood vessels that the therapeutic potential of 
NO was realized.10,11 Since a scientific explosion towards understanding the physiological role of NO has 
taken place and revealed that the effects are ubiquitous, although highly concentration dependent (see 
chapter 1). Towards this end the utility of NO therapeutic materials has been investigated for applications 
spanning the spectrum between regeneration of healthy tissues and as chemotherapeutics.1,12-16 However, 
the practical application of therapeutic NO materials requires careful dosage tuning in order to illicit a 
desired response.   
While the importance of NO is recognized there is much debate regarding the feasibility and utility of use. 
One such example is the effects of NO towards stimulating the angiogenic growth of blood vessels. As 
previously mentioned NO plays a critical role as the endothelial relaxation factor and it is hypothesized 
that it is also responsible for stimulating angiogenic growth, however there is much debate in the 
literature regarding its ultimate effectiveness.17-20 From these reports it is clear that while in some 
instances the effects of NO are advantageous in other cases there is no clear effect. Prior to concluding 
whether or not angiogenic growth can be facilitated by NO it is crucial to evaluate the variability of NO 
materials that are used including the type of NO material, the concentration of the donor, and also the type 
of media used for these experiments must be taken into consideration.  As a result of isolating the 
different types factors used we can thereby determine the therapeutic range of NO required for angiogenic 




The determination of accurate NO dosage to achieve a desired cellular response is imperative towards the 
effective use of NO materials. While the variable NO release rates from donors is an obvious factor when 
it comes to selecting an appropriate material, the influence of the reaction medium is often overlooked.6,7 
Often times experiments aimed at determining the instantaneous amount of NO released from the 
materials and evaluation of subsequent cellular responses are performed as an independent experiment 
where NO release measurements are carried out in inert buffer solutions compared to the complex 
biological mediums that are used for in vitro studies.  
In order to accurately measure the amount of NO that is available to elicit a cellular response, an effective 
method for evaluating the total NO released from NO donors under in vitro conditions is highly desirable. 
Cell and tissue culture media are composed of 3 primary additive groups: amino acids, inorganic salts, 
and vitamins. Formulations vary based upon manufacturer, media type, and the addition of supplemental 
serum. The complexity of cell media solutions combined with the reactive nature of NO provides ample 
opportunity for the presence of scavengers to reduce the amount of available NO. As such, the 
identification of potential scavenging agents present in the cell media solution that can potentially 
interfere with the availability of NO from donors is essential towards understanding concentration 
mediated effects of NO in cells through in vitro studies.    
Common spectroscopic and electrochemical methods for the direct and indirect measurement  of NO 
include the Griess assay,21,22 electrochemical sensors,23 and chemiluminescence detectors.24 Recently, the 
Schoenfisch group surveyed the use of these commonly used methods for their ability to quantitatively 
measure NO in a range of media types.7 This work demonstrated significant differences in the amount of 
NO measured using each technique, where chemiluminescence was the only method that provided 
accurate quantification of total NO based upon the theoretical payload of the sample. The ability to 
measure the NO payload from NO-releasing materials is highly valuable for determining the total amount 
of NO that is available to target sites.  Traditionally, the release of NO from materials is evaluated in 




the sampling medium from PBS to a biologically-relevant media, such as saliva, urine, and cell growth 
media, results in significant variations in the amount of detected NO.7  
In this work a chemiluminescence based sampling method for quantifying the NO release from two 
classes of common NO donors, N-diazeniumdiolates and S-nitrosothiols, in carbonate buffered media 
routinely used for endothelial and neural cell lines is presented. While cell culture experiments require 
aerobic conditions, chemiluminescence measurements of NO are conducted in an anaerobic environment 
in order to determine the NO scavenging effects of cellular media solutions without interference 
associated with the rapid reactivity of NO with O2. The NO scavenging effects of each media type are 
determined by a direct comparison of the measured amount of NO in inert buffer solution. The extent of 
scavenging was found to be variable based on the cell media used and the half-life of NO generation from 
each donor. Upon closer inspection of the subtle differences in media composition it was determined that 
the vitamin additive riboflavin is the principal scavenging agent in a concentration dependent manner. 
These findings are significant for the accurate quantification and reporting of bioavailable NO generated 
from NO materials used under in vitro conditions.  
Experimental Methods 
Materials.  All reagents were obtained from commercial vendors and used without further purification:  
N,N’-dimethyl-1,6-diaminohexane (TCI America), L-cysteine, (98%, Alfa Aesar), spermine, (97%, Alfa 
Aesar), t-butyl nitrite, (90%, Aldrich), riboflavin, (98%, Alfa Aesar), L-tryptophan, (99%, Alfa Aesar), L-
tyrosine (97%, Aldrich), sodium hydroxide (Fisher Scientific), cupric chloride dihydrate (99%, Fisher 
Scientific), phosphate buffered saline tablets (EMD), and acetonitrile (EMD).  Cell media solutions of 
MCDB 131, without glutamine (EC media) and neurobasal A (NB media) were obtained from Invitrogen 
and used without further modification. Compressed gasses were obtained from commercial vendors of 
nitrogen, 99.999%, oxygen, argon, 5% carbon dioxide balanced with nitrogen were supplied by Airgas 




Preparation of NO donors. 1) Diazeniumdiolates were prepared in accordance with previously published 
procedures.26 In brief, to a specialized pressure vessel, 500 mg of the parent amine, N,N’-dimethyl-1,6-
diaminohexane for MAHMA/NO or spermine for SPER/NO, was added to 40 mL of acetonitrile 
equipped with a stir bar. The vessel was sealed and attached to a specialized NO reactor. The vessel was 
purged with argon gas to remove any oxygen, followed by the introduction of 80 psi of NO. The amine 
was reacted with NO under pressurized conditions for 24 h, after which time the diazeniumdiolate formed 
as a white precipitate. The product was filtered, washed with acetonitrile (3 x 30 mL), and dried under 
vacuum to remove residual solvents. The diazeniumdiolates were evaluated for purity by UV-vis 
spectroscopy based on the characteristic absorbance feature at 252 nm.  More specifically, each donor 
was prepared at 0.1 mM in sodium hydroxide (0.1 mM) and quantified according to the absorbance value 
at 252 nm (ε=7300 M-1 cm-1 for MAHMA/NO and  ε=8500 M-1 cm-1 for SPER/NO.) The prepared NO 
donors were stored in the freezer. 2) S-nitrosothiols: S-nitrosocysteine (CysNO) was prepared by adding 6 
x 10-5 mol t-butyl nitrite to an ice cold solution of 0.05 M L-cysteine in 1 mL of DI water. The reaction 
was stirred in an ice bath for twenty minutes until the solution was a transparent, dark red. The resulting 
concentration of CysNO was determined by UV-vis spectroscopy via an absorption feature at 545 nm ( 
ε=15 M-1 cm-1).    
Quantification of NO. Nitric oxide was quantified using a GE chemiluminscence-based nitric oxide 
analyzer (NOA). In brief, 15 mL of sampling solution (PBS or cell media) was added to a customized 
NOA sampling vessel fitted with a pH probe. The headspace of the reaction vessel was sampled 
continuously at a rate of 200 mL min-1. A nitrogen flow gas was introduced into the system headspace at a 
rate of 184 mL min-1 and simultaneously bubbled into the solution at 16 mL min-1. In experiments using 
cell growth media, the bubbling gas was substituted for a 5% CO2, 95% N2 in order to maintain a pH of 
7.4. The injection port was capped and a micro-sized pH probe connected to a pH meter (Fisher 50x 
series) was inserted into the side-port.  The NOA was calibrated with 0 and 45 ppm NO standards. The 




37 °C using a circulating water bath. Aliquots of the NO donor solutions were introduced into the sample 
injection port using a glass Hamilton syringe to give an initial solution concentration of 1 x 10-6 M. The 
resulting NO release was recorded in 1 s intervals. NO release for CysNO is initiated by a copper catalyst. 
As such catalytic amounts of Cu2+ ions (5 mol%  Cu2+ compared to CysNO)  was added to the reaction 
solution from a 1 x 10-6 M stock solution of CuCl2. The theoretical amount of total NO was determined 
based on the initial concentration of NO donor added to the system. The concentration of the stock NO 
donor solution was determined by UV-vis, as described above.  
NO Scavenging Experiments based on cell media. Riboflavin and tryptophan were examined as 
components of the cell media with the potential to act as NO scavengers. Stock solutions of 1 mM 
tryptophan and 0.1 mM riboflavin were prepared in Millipore purified water (18 MΩ resistance). In order 
to mimic the EC and NB media conditions, riboflavin and tryptophan were added to PBS (15 mL) at 
concentrations corresponding to those found in the commercially available cell media solutions. The 
concentration of riboflavin differed by two orders of magnitude between EC and NB media and was 0.01 
µM and 1.06 µM, respectively. The media concentration of tryptophan in EC and NB media was 20.1µM 
and 78.4 µ M, respectively. A complete list of additives  for each media type is provided in the supporting 
information (see Table S1). MAHMA/NO was added at an initial concentration of 1µM  to the 
riboflavin/tryptophan PBS solutions. The scavenging efficiency of the additives was determined based on 
the quantified NO with each additive evaluated individually as well as in combination. Each experiment 
was performed at n > 3 with the averages and standard deviations reported. 
Scavenging agent ratio effects. In the first set of experiments the ratio of riboflavin was varied with 
respect to reducing agents, tryptophan or tyrosine. Stock solutions of 0.1 mM MAHMA/NO, 0.1 mM 
riboflavin, 10 mM tryptophan, and 0.1mM tyrosine were prepared in DI water. Experiments were 
performed in PBS at pH=7.4. In each experiment the concentrations of MAHMA/NO and riboflavin were 
maintained at a 1:1 ration at 0.001 mM. Tryptophan or tyrosine were added to the reaction between 1 and 




1:1000 with riboflavin the concentration of riboflavin anf MAHMA_NO were reduced to 0.1 µM and 
tyrosine was kept at the stock concentration of 0.1mM prepared directly in PBS. In experiments where the 
effects of riboflavin versus the concentration of NO were evaluated by maintaining a fixed concentration 
of riboflavin (1 µM) and tryptophan (100 µM). The concentration of the MAHAM/NO as the NO donor 
was then varied between 0.1 µM and 10 µM. The resulting NO was quantified by chemiluminescence. 
The amount scavenged NO was calculated by subtracting the theoretical yield of NO from the actual 
yield.   Each experiment was performed in triplicate.  
Statistical Analysis. Statistical t-tests were performed on each data set to determine statistical differences 
at the 95% confidence interval.  
Results and Discussion 
Sample Chamber Design. Nitric oxide release from NO donors was evaluated in PBS or cell media 
solutions using chemiluminescence based detection. Traditionally, nitrogen is used as an inert carrier gas 
for chemiluminescence measurements where it is introduced into the headspace of the vessel and bubbled 
directly into the solution (see Figure 1). In the case of cell media solutions, a 5% CO2 / 95% nitrogen 
carrier gas is employed in order to maintain the solution pH in the range of typical cell culture protocols, 
and to mimic the percentage of CO2 in the blood stream. In order to ascertain that the solution pH is 
maintained in the appropriate range, the sampling setup was fitted with a pH probe for continuous 
monitoring. The initial pH of the media was 7.65; after 10 min of CO2/N2 bubbling into the solution, the 
pH reached 7.4 and was maintained for the duration of the experiment.  
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Prior to this work, real-time accurate quantification of NO generated in biological media using 
chemiluminescence has been difficult due to the ability to maintain the pH of the carbonate buffer in the 
physiological range.  Maintaining a constant pH of 7.4 is important for two reasons: first, cell studies are 
performed at a constant pH of 7.4 which imitate body conditions, and with  deviations of + 0.15 units 
causes cell death,25 and second, both N-diazeniumdiolates and S-nitrosothiol NO donors are well known 
to have pH dependent decomposition mechanisms.26 By measuring the pH over the course of the reaction, 
we ensure that any observed differences in NO release across various media is a direct result of the 
medium and not changes in the reaction environment. Since CO2 does not react with NO under these 
conditions, substitution of CO2 for part of the nitrogen carrier gas allows the buffer capacity to be 
maintained without disrupting the gas flow that is required to maintain accurate kinetics measurements. In 
the absence of CO2 gas, the pH of the media increased to 9.7, which is unsuitable for biological 
applications; whereas, when CO2 is added at a rate of 16mL min-1, the pH of the solution is maintained at 
pH 7.4. 
Figure 1. Measurement setup for the real-time quantification of NO released in media solutions with 
simultaneous monitoring of pH.  
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NO Quantification from NO Donors in Biological Media. The generation of NO from N-
diazeniumdiolates and S-nitrosothiol donors in various in vitro conditions was investigated by considering 
PBS, endothelial cell medium (EC medium) and neurobasal cell medium (NB medium). The NO donors 
selected for this study are the N-diazeniumdiolates MAHMA/NO and SPER/NO  and the S-nitrosothiol 
CysNO, shown in Figure 2. As a basis for comparison, we first determined the total payload of each 
donor using standard measurement method in PBS. The amount of NO recovered from each donor in the 
various cell media solutions was then compared to the total recovered in PBS (Figure 3). In EC medium, 
the total amount of NO measured from the decomposition of either  MAHMA/NO  or CysNO  was not 
statistically different  at the 95% confidence interval compared to measurements in PBS. However, 
substitution of the NO donor for SPER/NO in EC medium resulted in a statistically significant difference 
compared to PBS, with a 30% decrease in the amount of measured NO. Experiments performed with NB 
medium resulted in a 60% decrease in NO recovery compared to PBS for MAHMA/NO and CysNO, 
while SPER/NO in NB medium resulted in complete suppression of the measureable NO.  
 
The generation of NO from the investigated donors is contingent on environmental conditions, including 
temperature and pH. The decrease in the total NO release over the course of the experiment  observed in 
the cell media could be attributed to either incomplete decomposition of the NO moiety or rapid 
scavenging by media components. The pH of the medium environment significantly influences the 
stability of the NO donor, ultimately leading to variability in the rate of NO release that can contribute to 
Figure 2. The NO donor investigated included the N-diazeniumdiolate donors a) MAHMA/NO b) 
SPER/NO and the S-nitrosothiol donor c) CysNO. 
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discrepancies in the amount of recorded NO. In order to ascertain if the observed discrepancies in NO 
recoveries across the different media types is due to fluctuations in pH, we continuously monitored the 
solution pH for the entire duration of the measurement for each media type and donor (Table 1). In each 
case, the reaction pH was consistent and maintained in the physiological range, indicating that there are 
not differences in the NO recoveries due to pH changes over the course of the NO releasing period. 
Additional evidence to support that the medium environment does not impact the release of NO from each 
donor is provided by the NO release half-lives shown in Table 1. Half-lives are based on the total amount 
of NO recovered from each experiment and reported as the time when half of the NO was measured. For 
each NO donor, the half-life of NO generation, regardless of the total amount recovered from the cell 
media solutions, remained consistent with the half-life observed for PBS, which indicates that, of the total 
amount of NO that is released, the kinetics of the NO release does not change, only the amount of NO 
changes in a given period of time. On the basis of these results, we can conclude that the decrease in 
measured NO is a direct result of NO scavenging by media components rather than stabilization of the 
NO donor moiety. In order to properly report the necessary dosage of NO for stimulating a cellular 
response, it is essential to determine which components of the cell media are responsible for the 
scavenging of NO in each individual media.   
Figure 3. Comparison of the cell media solutions to PBS based upon the total amount of NO 
recovered from each NO donor. The * denotes a significant difference at the 95% 





NO donor Media t1/2 (min) pH 
MAHMA/NO PBS 1.3 ± 0.5 7.37 ± 0.02 
MAHMA/NO EC 1.2 ± 0.4 7.39 ± 0.01 
MAHMA/NO NB 1.9 ± 0.7 7.38 ± 0.02 
CysNO PBS 6.5 ± 0.8 7.37 ± 0.01 
CysNO EC 6.7 ± 0.6 7.38 ± 0.02 
CysNO NB 7.6 ± 0.8 7.39 ± 0.03 
SPER/NO PBS 32.8 ± 4 7.38 ± 0.02 
SPER/NO EC 30.8 ± 2 7.39 ± 0.03 
SPER/NO NB n/a 7.38 ± 0.02 
Effect of Media Additives. The significant difference in NO recovery amounts between EC medium and 
NB medium for each of the NO donors examined suggests that media additives play a crucial role in the 
availability of NO. It is important to note that the scavenging experiments were performed without the 
addition of supplemental serum that is regularly used in cell culture experiments. Constituents of serum 
often include growth factors, proteins, hormones, and vitamins that could potentially increase NO 
scavenging. In this work the primary concern is the identification of NO scavenging agents found as 
additives in cell media solutions.  In Appendix A a complete list of the media components for EC and NB 
media as provided by the manufacturer.  Comparison of the additive lists indicated that the concentration 
of riboflavin (vitamin B2) in NB media (1.06 x 10-3 M) exceeded that of the EC media (1.01 x 10-5 M ) by 
two orders of magnitude and exceeded the initial concentration of NO donor (1 x 10-6 M)  for both media 
"#!
types. As an essential nutrient in promoting cellular growth, riboflavin is a common additive in cellular 
media; however, the concentration is varied based on cellular needs. Riboflavin and has been cited 
previously as an NO scavenging agent in the presence of oxygen by facilitating the generation of 
superoxide, resulting in the generation of peroxynitrite upon reaction with NO.45 By studying the effect of 
riboflavin as an NO scavenger under conditions found for cell media used for in vitro studies, we were 
able to highlight an alternative pathway for NO scavenging by riboflavin.  
As a member of the flavin family of compounds, riboflavin is able to undergo 1 and 2 electron reductions 
to form the radical semiquinone or hydroquinone species in the presence of a proper oxidant, see Figure 
4.27 Tryptophan, an essential amino acid added to cell media solutions, has been noted as early as the 
1950s as an oxidant for the reduction of riboflavin to the reactive radical semiquinone.28 As a radical 
species, NO is especially susceptible to the reaction with the radical semiquinone species in the form of a 
radical-radical reaction. In order to evaluate the hypothesis that the riboflavin-tryptophan complex is an 
active NO scavenging agent in cell media solutions, we simulated the concentrations of both riboflavin 
and tryptophan from each of the cell media types using PBS as our reaction medium.   
 
Figure 4. The various oxidation states of the flavin family: flavin undergoes a two electron reduction 




In Figure 5, the NO scavenging efficiency of riboflavin and tryptophan, used independently and in 
combination, is compared to results in PBS and the respective medium types using MAHMA/NO and 
SPER/NO as the source of NO. For experiments designed to mimic the concentrations of riboflavin and 
tryptophan in EC media, using MAHMA/NO as the donor, the amount of NO recovered was not 
statistically different at the 95% confidence interval compared to either PBS or EC media (Figure 5a). 
However, at the elevated concentrations for each component found in NB media, the measured NO for the 
combined use of riboflavin and tryptophan was statistically equivalent to results observed for NB media 
(Figure 5b).  At NB concentrations with MAHMA/NO, the scavenging efficiency of riboflavin alone was 
only half as efficient at scavenging NO compared with the riboflavin-tryptophan combination. Compared 
to PBS, the riboflavin-tryptophan complex scavenged 60% of the available NO. The sole use of 
tryptophan, however, did not statically alter the amount of measured NO when compared to PBS buffer.  
The relatively short half-life of MAHMA/NO (t½ = 1.3±0.5 min at 37 °C, pH 7.4,) results in the release of 
a bolus of NO, elevating the concentration of NO in solution at a rate that exceeds the scavenging 
potential of the riboflavin-tryptophan complex. To explore this effect, we have paralleled our scavenging 
experiments with the use of SPER/NO (t½ = 33±4min at 37 °C, pH 7.4). When added to a solution 
containing both riboflavin and tryptophan under EC conditions, the total amount of measured NO is 
statistically equivalent to the results obtained for EC media (Figure 5c). Similarly, NO release was not 
observed for the riboflavin and tryptophan experiments in NB conditions (Figure 5d). Based on our 
results with MAHMA/NO, we expect that the use of riboflavin alone will have a pronounced effect on the 
amount of NO recovered at both the EC and NB media concentrations using SPER/NO as the donor. 
Under NB type conditions, NO release was not measureable whereas under EC conditions, the amount of 
NO recovered was not statistically different from results obtained for the PBS control. In concurrence 
with results from MAHMA/NO, the sole use of tryptophan did not result in a statistical difference in 




Effect of scavenging agent ratios. The cell media solutions used in this work differ in riboflavin 
concentration by two orders of magnitude and drastic difference in NO scavenging were observed. 
Furthermore, the ratio of riboflavin to tryptophan varied significantly at 1:100 and 1:1000 for NB and EC 
media, respectively. As a result, in order to evaluate the role of riboflavin and tryptophan concentrations 
with respect to NO scavenging, the relationship between riboflavin and tryptophan must be considered 
Figure 5. Comparison of NO release in PBS solutions with riboflavin and tryptophan added at 
concentrations that correspond to the varying media types a) MAHMA/NO under EC media 
conditions, b) MAHMA/NO under NB media conditions, c) SPER/NO under EC media conditions, 
d) SPER/NO under NB media conditions. Values are reported as an average ± standard deviation for 




along with the ratio of NO to available riboflavin.  This will in turn be useful for predicting the extent of 
scavenging in media types not addressed in this work by providing a general understanding of the role of 
riboflavin and tryptophan as NO scavengers.  
Riboflavin is identified as the reagent primarily responsible for NO scavenging, whereas tryptophan alone 
has no effect as shown in Figure 5b; however, the addition of tryptophan to a solution containing 
riboflavin notably enhances the incidence of scavenging. The scavenging efficiency of riboflavin is 
attributed to the abundance of reduced riboflavin in the solution.  Therefore, by increasing the ratio of 
tryptophan in solution there is an increase in the amount of the semiquinone scavenging species in 
solution. To examine the optimal ratio of tryptophan:riboflavin needed to maximize scavenging, we 
varied the ratio between zero and one thousand equivalents of tryptophan to riboflavin, shown in Figure 6. 
In each of these experiments, the ratio of riboflavin to NO remained constant. In the absence of 
tryptophan, riboflavin scavenges approximately 40% of the available NO in the system. The addition of a 
single equivalent of tryptophan to the solution does not enhance the scavenging efficiency compared to 
riboflavin alone. As the ratio of tryptophan is further increased to 10, 100, and 1000 equivalents there is a 
notable increase in the NO scavenging. The most efficient riboflavin : tryptophan ratio was noted to be 
1:100, scavenging 70% of the NO generated. Further increasing the amount of tryptophan to a 1000 fold 
excess did not enhance the efficiency of scavenging; instead a slightly diminished efficiency of NO 
scavenging was noted.  
With the numerous additives in cell growth media, the likelihood of additional reducing agents for 
riboflavin is high. Of these components tyrosine, a non-essential amino acid, is known to facilitate charge 
transfer reactions with flavin compounds. In the cell media solutions investigated, the concentration of 
tyrosine is 100 µM and 4 µM in EC and NB media, respectively. Similar to experiments with tryptophan, 
we varied the ratio of tyrosine to riboflavin and quantified the amount of resulting NO, Figure 6.  
Analogous to tryptophan, there is no increase in the scavenging efficiency when tyrosine is used at a 1:1 




observed at a 10 fold excess. Further additions of tyrosine to 100 and 1000 fold excesses do not contribute 
to an increase in scavenging beyond the 50% observed at a 10 fold excess. In comparison to tryptophan, 
tyrosine is a less effective reducing agent with riboflavin when considering NO scavenging. 
 
Figure 6. NO scavenging efficiency of riboflavin at variable ratios of reducing agents tryptophan or  
tyrosine. Values are reported based on the percentage of NO that is scavenged.  Values are reported for 
triplicate measurements at the 95% confidence interval. 
 
As such, the combined use of tryptophan and tyrosine increases the ratio of the reducing agent to 
riboflavin to over a 1000-fold excess for both media types. However, we have established that, despite the 
increasing presence of reducing agents, it is the riboflavin concentration that ultimately dictates 
scavenging. To investigate the combined effects of tyrosine and tryptophan on NO scavenging with 
riboflavin, we performed experiments that mimicked the conditions found for EC and NB media types. 
Using MAHMA/NO as the NO donor, we found that tyrosine/tryptophan experiments did not impact the 
observed scavenging when compared to results with cell media. As a result, it is clear that the ratio of 
riboflavin to reducing agents is important. Once the concentration of reducing agents exceeds the 
threshold of efficacy, further increasing the concentration of reducing agents does not influence the 




Now that we have established the role of reducing agents towards NO scavenging, we must consider the 
effect of the absolute concentrations of NO and riboflavin towards scavenging. In experiments using the 
two cell media formulations, the amount of riboflavin present in solution differed by two orders of 
magnitude, resulting in very little NO scavenged in EC media compared to large scavenging effects in NB 
media. This indicates that, in addition to the riboflavin : tryptophan ratio, the amount of riboflavin 
compared to NO also plays a role. To determine the effect of riboflavin concentration on the amount of 
NO scavenging, we varied the ratio of NO donor to riboflavin from 10:1 to 1:10 in 5 equivalent 
increments, shown in Figure 7. It is important to note that since we are using a diazeniumdiolate as the 
NO donor, each equivalent actually produces 2 equivalents of NO. In these experiments, a fixed 




Figure 7. NO scavenging efficiency of riboflavin at variable ratios of NO donor.  Values are reported 
based on the percentage of NO that is scavenged.  Values are reported for triplicate measurements at the 





In experiments where the concentration of NO donor exceeded the amount of riboflavin 10:1, scavenging 
was not observed, Figure 7. As the ratio of riboflavin increased at increments of 5 equivalents, the 
efficiency of scavenging was enhanced with 95% of the NO scavenged when riboflavin was in 10 molar 
excess to the NO donor. With each successive 5 equivalent increase in the riboflavin concentration with 
respect to NO donor, the scavenging efficiency was increased, see Figure 7. These results indicate that for 
the most effective scavenging of NO is observed when the concentration of riboflavin is in excess of the 
NO in the system. This was especially evident when we compared the NO scavenging results between 
MAHMA/NO and Sper/NO in the cell media.  
Conclusion 
The determination of NO dosages required to elucidate a cellular response necessitates that the effects of 
the cell media solutions on NO availability be accounted for. In this work, a method is established for 
measuring the amount of available NO released from NO donors when added to cell media solutions 
whose pH is maintained using a carbonate buffer system. The complexity of the media solutions offers a 
rich environment for the reaction of NO with various components. Variations in the riboflavin content of 
the cell media was found to result in scavenging of NO. The efficiency of NO scavenging by riboflavin 
was deduced to be dependent on the absolute concentration of riboflavin with respect to the concentration 
of NO. In addition, riboflavin scavenging efficiency was found to be dependent on the presence of 
reducing agents, including tryptophan and tyrosine, in an excess of at least 100 fold to achieve maximum 
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The traditional approach to NO materials is based on the incorporation of an exogenous supply of NO. 
While this approach is effective for inhibiting surface biofouling the effects are often short lived due to 
the finite reservoir of incorporated NO. Instead the development of NO materials with sustained NO 
release must rely on renewable sources of NO supplied in the blood stream as S-nitrosothiols. As such the 
incorporation of Cu catalysts into the matrix of polymeric materials facilitates the surface localized 
generation of NO from bioavailable substrates. Metal organic frameworks (MOFs) are robust and 
versatile materials with emerging interest in biomedical applications and are explored in this work for 
their potential as NO catalysts.    
The reactivity of the archetypal Cu-MOF, CuBTC, as a catalyst for NO generation from RSNO substrates 
was determined based on the real time measurement of NO. Catalytic turnover was observed for CuBTC 
where repeat usage did not impact the reactivity of the catalyst. The selectivity of CuBTC towards 
RSNOs was determined based on variations in substrate size and polarity of incorporated functional 
groups. Structural integrity of CuBTC following reaction with the RSNOs was evaluated by assessing the 
resulting crystallininty of the reacted particles via powder X-ray diffraction (pXRD). Finally, the 
influence of the metal ion used in the construction of the framework towards reactivity with RSNOs was 
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determined using iron and aluminum based MOFs. This work represents a proof of principle for the use 
of MOFs as NO catalysts, however substantial improvements in the aqueous stability of the framework 
are needed for biological applicability. 
Introduction 
Metal organic frameworks (MOFs) are a unique class of solid state materials whose periodic assembly of 
coordination clusters of metal ions and organic linking ligands, referred to herein as secondary building 
units (SBUs), results in the formation of a porous crystalline network in 1, 2, or 3 dimensions.1-3 As a 
result an infinite combination metal ions and ligands of MOFs can be tuned for a wide range of 
applications including gas storage,4-6 chromatography,7-9and catalysis10-12 to name a few. MOFs initially 
drew strong correlations to zeolites and were touted as being up and coming versatile materials for 
numerous industrial applications. However unlike zeolites which have a strictly inorganic composition 
and can withstand temperatures in excess of 1000 °C, the organic component of MOFs restricts the 
thermal stability of MOFs up to 500 °C.3 Furthermore, the SBUs dictate the structural and chemical 
features of MOFs and are governed by the constraints of metal ligand coordination chemistry and are 
therefore subject to stability considerations in air and in solution. As a result through the rational design 
of frameworks based on the judicious selection of metal ions and ligands MOFs can be tailored for 
specific applications.  
An emerging field of interest for the application of MOFs is in biomedicine as imaging contrast agents,13 
drug delivery vehicles,14-16 and as bioinspired catalysts.17,18 First and foremost the preparation of MOFs 
for biomedical applications necessitates a biofriendly composition that will not result in adverse effects or 
toxicity related complications once in use. To date studies regarding biocompatibility of MOFs are scarce, 
however rational design of bioMOFs dictates that only metal ions that are innate to the biological 
environment including Fe, Ca, Mg, Zn, or Cu should be used. As for the ligands polycarboxylic or 




clearance from the body.14,19 Considering the porous nature of MOFs the most facile route to use in 
biomedicine is the encapsulation of therapeutic agents and the subsequent deliver through host/guest, 
diffusion, or degradation processes. In particular, nitric oxide (NO) can be incorporated into the 
framework in accordance with traditional MOF gas storage approaches as a physisorbed guest or it can be 
grafted onto functionalities contained within the framework in an approach known as post synthetic 
modification.15,20-24 As far as NO materials are concerned MOFs functionalized with exogenous NO 
report the highest loading capacities of any material to date, however uncontrollable release kinetics and 
ultimate depletion of the NO reservoir remain a limiting factor for their use.25 While the release of large 
boluses of NO is known to have immediate positive effects as an antimicrobial agent, long term effects 
aimed at preventing surface deposition of fouling agents on device surfaces and regenerative effects 
require the sustained and controlled delivery of NO for periods in excess of a year.   
The design of long term NO materials requires the use of endogenous NO donors rather than the direct 
incorporation of exogenous NO donors into the material matrix. Readily available NO donors found 
circulating in the blood stream in concentrations up to 10 uM as NO storage and transport vehicles are 
RSNOs.26,27 The liberation of NO from RSNOs is known to proceed via a Cu2+ catalyzed reaction shown 
in equation 1.28,29 As such the design of MOF NO catalysts should be equipped with Cu2+ metal ions as 
the active site. The use of MOFs as biocatalysts is an emerging field that is dominated by the inclusion of 
protein mimetic active sites, such as porphyrin macrocycles,17,30 as a component of the ligand in the 
construction of the framework. The use of these bioinsipred MOF catalysts have shown to be successful 
for mediating many charge transfer based reactions, however the increased size and flexibility of the 
framework imparted by the active site containing ligands results in collapsible frameworks generally 
requiring use only in the gas phase.18,30 As an alternative MOFs with coordinatively unsaturated metal 
centers in the SBU are effective for catalyzing many organic reactions and exhibit structural robustness 
over both gas and solution phase reactions.  
"#!
For purposes of this proof of principle work the commercially available Cu-MOF, CuBTC31 was selected 
as the investigated MOF NO catalyst. CuBTC is amongst the most researched frameworks to date owing
to its archetypal assembly into a robust porous (9Å x 9Å) 3-dimensional framework with coordinatively 
unsaturated Cu2+ metal centers and limited hydrolytic stability.32-34 The SBU of CuBTC is consists of two 
octahedrally coordinated Cu2+ ions coordinated to the carboxyl functionalities of 1,3,5-
benzenetricarboxylic acid (BTC) bridging ligands forming a carboxylate paddle wheel complex, shown in 
Figure 1a.31 The axial positions of each Cu2+ ion are occupied by labile water molecules, which upon 
dehydration results in a Cu-MOF with coordinatively unsaturated metal ions available for driving 
catalytic reactions. The accessibility of Cu active sites, hydrolytic stability, and large pores of CuBTC 
make it a promising choice for investigating the potential reaction with RSNO substrates resulting in the 
catalytic generation of NO, Figure 1b.  
 
Figure 1. a) Dinuclear Cu2+ Carboxylate paddlewheel active site of CuBTC. B) Illustration of RSNO 





The suitability of a MOF as an NO catalysts is contingent upon the structural stability of the material 
under the reaction conditions and the capacity of the material to catalytically generate NO from 
bioavailable RSNO substrates. The reactivity of the CuBTC with bioavailable RSNO S-nitrosocysteine 
(CysNO), according to equation 2, was evaluated by directly monitoring the formation of the product NO. 
The structural integrity of CuBTC was determined based upon the characteristic diffraction patterns of the 
material obtained by pXRD and analysis of the reaction solution for Cu resulting from degradation of the 
framework. Subsequently, the relationship between substrate structure and reactivity with CuBTC was 
examined using seven RSNO substrates that differed based on size and polarity of incorporated functional 
groups. Finally, the role of the metal ion contained within the framework was evaluated in order to 
confirm the necessity of having a Cu metal center as the active site.     
 
Experimental Methods 
Materials.  All reagents were purchased from commercial vendors and used without further purification. 
Cu3(BTC)2 was purchased as Basolite C300 from Aldrich (St. Louis, Missouri).   Mercaptans used in this 
work include L-cysteine (Alfa Aesar), cysteamine (Fluka), thioglycolic acid (Sigma-Aldrich), thiolactic 
acid (Sigma-Aldrich), 2-mercaptoethanol (Amresco), D,L-homocysteine (Sigma-Aldrich), and 3-
mercaptopropionic acid (Sigma Aldrich). Reagent grade ethanol (96%) was purchased from Mallinckrodt 
Chemical (Phillipsburg, New Jersey), and t-butyl nitrite (90%) was purchased from Acros Organics (New 
Jersey, USA). Ultra high purity N2 and O2 gases for the NOA measurements were supplied by Airgas 





MOF Activation. Cu3(BTC)2 was activated by heating the material to 100 C under vacuum for 8 hours. 
Following activation the materials were stored under desiccant until use. After activation the material 
underwent a color change from unactivated cyan blue to a very dark blue. A comparative evaluation of 
the effect of activated and unactivated Cu3(BTC)2 for CysNO decomposition was done according to the 
previously specified procedure. It is of note that upon addition to the ethanol solution the activated 
particle immediately assumed the light cyan blue color of unactivated materials due to interaction with the 
solvent.  A comparison of the NO release profiles is shown in SI figure 1. The resulting NO release 
profiles indicate that there is initially an increase in the rate of the reaction, however the same trend is 
observed in both cases. Therefore, in order to maintain consistency in the initial extent of hydration all 
experiments reported here in utilized the activated materials.  
Preparation of S-nitrosothiols. RSNOs were prepared in situ by adding 5x10-5 mol of the appropriate thiol 
to 1mL of Millipore water followed by addition of excess (1x10-4 mol) nitrosating agent, t-butyl nitrite. 
For each of the thiols investigated, the reaction solution was covered and protected from light with an 
aluminum foil wrapper and placed in an ice bath at 0 °C. After 15 min, the reaction solution was purged 
with N2 under vacuum for 5 min to remove unreacted t-butyl nitrite. Complete removal of t-butyl nitrite 
was verified by UV-Vis spectroscopy following the disappearance of the characteristic 6 point absorbance 
features between 330-410 nm. The concentrations of the RSNO solutions were monitored by UV-Vis 
spectroscopy following the absorbance band at 545 nm.  
Determination of molar extinction coefficients of RSNOs. S-nitrosothiols were prepared from a stock 
solution of 0.05 M thiol with 2x excess of t-butyl nitrite added as the nitrosating agent. After reacting in 
an ice bath for 15 min the solution was purged with N2 to remove the excess t-butyl nitrite and the system 
was evacuated under vacuum to assure complete removal of residual t-butyl nitrite. Using a UV-vis 
spectrometer the maximum absorbance feature at 545 nm for each RSNO was recorded. Under the 
conditions of excess nitrosating agent, 100% conversion of the thiol moieties to RSNOs was assumed. 




thiol concentration assuming complete nitrosation based on the resulting absorbance value. Each 
experiment was done in triplicate and the resulting molar extinction coefficients for each RSNO are as 
follows: Thiol: λ(nm), (ε(M-1 cm-1));  S-nitrosocysteine (CysNO): 545, (14.5); S-nitrosocysteamine 
(CysamNO): 545, (14.5)); S-nitrosohomocysteine (HcysNO): 545, (16.5); S-nitroso-3-mercaptopropionic 
acid (MPANO): 550, (15.8); S-nitrosothioglycolic acid (TGANO): 545, (16.5); S-nitrosothiolactic acid 
(TLANO): 545, (16.5); S-nitrosomercaptoethanol (MeNO): 545, (13.8).  
Quantification of NO. Direct NO measurements were made using chemiluminescent detection with a GE 
280i Nitric Oxide Analyzer (NOA). In reactions requiring a catalyst, the catalyst was added prior to the 
addition of RSNO. The MOF catalyst, Cu3(BTC)2 was added directly to the NOA reaction vessel prior to 
the addition of the solvent. Using an analytical balance accurate to the one ten thousandth of a gram a 
total of 0.1 mg Cu3(BTC)2 totaling a copper content of 0.5 µmol Cu2+.  A 0.5 µmol aliquot of CuCl2 · 
2H2O was injected from a 0.05 M stock CuCl2 · 2H2O directly into the solvent solution. The solvent 
ethanol was added in 2 mL quantities to a specialized reaction vessel and was deoxygenated with a flow 
of N2 gas set to 200 mL/min with a simultaneous sampling rate of 200 mL/min under vacuum into the 
NOA reaction chamber. The reaction vessel was protected from light with aluminum foil wrapping and 
exposed to ambient temperature at 22 °C. An aliquot containing 1 µmol RSNO (2x10-5 L stock solution) 
was introduced to the reaction flask via a side injection port. The resulting NO product was collected at 
one second intervals and processed using Microsoft Excel 2010. All experiments were performed in 
triplicate and the average and standard deviation reported for the total NO recovered (mol) and the half-
lives (s). 
pXRD measurements. Powder x-ray diffraction (pXRD) measurements were collected using a ScintagX2  
pXRD equipped with a Cu Kα (λ=1.5406 Å)radiation source. Scans were taken at a speed of 3°/min and a 




ATR-IR measurements. Infrared spectra was collected on a Nicolet 6700 FTIR spectrometer equipped 
with a diamond attenuated total reflectance accessory (ATR), Figure S3. All data was processed using 
Omnic 8 FTIR software.  All experiments were conducted in triplicate. 
Measurement of nonframeworkCuII. After the 2:1:1 CysNO:CysH: MOF-CuII reaction (experiment #5 in 
Table S1) was complete, the Cu3(BTC)2was removed from the reaction mixture.  The filtered ethanol 
reaction solution was evaporated, and the residual material was reconstituted with 2mL H2O. The 
resulting solution was evaluated for copper content according to EPA method 200.8 using a Perkin Elmer 
ICP-OES.2 The copper content was found to be 2.5 ± 0.6 x 10-7 M or 0.1% of the total MOF Cu2+ content. 
All experiments were conducted in triplicate and the average and standard deviation reported. 
Results and Discussion 
Solvent Stability Measurements of CuBTC. The stability of MOFs in aqueous environments is one of the 
critical challenges towards designing BioMOFs. CuBTC is a promising material because it has exhibited 
moisture stability, by coordinating H2O molecules and suggested for use as a desiccant. As such to begin 
the exploration of CuBTC as a MOF NO catalyst it is essential to investigate the robustness towards 
immersion in an aqueous environment. To this effect the structural integrity of CuBTC was evaluated 
following immersion in deionized water and also in phosphate buffered saline at pH7.4 in order to 
simulate mediums that are used for in vitro studies of biomaterials. The integrity of the material following 
aqueous immersion was evaluated by comparing the crystalline fingerprint of the starting material with 
the particles collected post immersion using pXRD, shown in Figure 2. CuBTC particles immersed in DI 
water for a 24h period resulted in irreversible alterations in the crystallinity of the material. This indicates 





Figure 2. Solvent stability studies of CuBTC after a 24h soak in water and ethanol at room temperature.  
Despite the lack of aqueous stability of CuBTC, the ultimate goal of this research is to demonstrate that 
feasibility of developing a MOF-NO catalyst. Therefore an alternative solvent medium must be explored 
which does not impact the stability of the framework, while allowing for the miscibility of the substrate. 
To this effect ethanol was investigated on the basis that it is used as the cosolvent in the synthesis of 
CuBTC and is also known to solvate low molecular weight RSNO species.31 As shown in Figure 2 
immersion of CuBTC in ethanol did not alter the crystallinity of the particles. As a result ethanol is the 
solvent medium selected for evaluating CuBTC as a MOF NO catalyst.       
Investigation of CuBTC as an NO Catalyst. The reactivity of CuBTC towards the generation of NO from 
CysNO in an ethanolic solution shown in Scheme 1 was assessed by measuring the resulting NO in real 




CysNO per Cu2+ active site are injected into the reaction medium is shown in Figure 3. NO release was 
sustained over a 10 hour period after which time the CysNO was fund to be depleted based on the total 
amount of NO recovered from the system indicating a catalytic turnover number of 2, shown in Table 1. 
In comparison to control experiments which did not contain a Cu catalyst and rather assessed the 
autocatalytic decomposition of CysNO after 10 hours only 17% of the available NO added to the system 
was recovered. These results are shown in conjunction with the CuBTC catalyzed NO release profile 
shown in Figure 3.  As such these results demonstrate that CuBTC can successfully catalyze the 
generation of NO from a bioavailable RSNO.  
 
Figure 3. NO release curves from the (red) uncatalyzed decomposition of CysNO and (black) CuBTC 
catalyzed decomposition of CysNO 
 The utility of CuBTC as a catalyst however requires that the material be effective as a catalyst with 
increased turnover efficiency. As shown in Table 1 when 10 and 15 fold excess of CysNO is added to the 
reaction system the turnover number was shown to increase accordingly. These results indicate that the 
catalyst is capable of propagating the reaction as long as there is available substrate for the reaction. In a 
separate study the feasibility of catalyst recycling was assessed. In this experiment CuBTC was reacted 
until completion with 2 equivalents of CysaNO, after which time CuBTC was removed from the reaction 
solution, rinsed, and added to a fresh solution containing an additional 2 equivalents of CysNO. This 
"#!
process was repeated in triplicate and the resulting NO release profiles for the 4 trials is shown in Figure 
4.  Notably the reactivity of the fresh CuBTC catalyst is faster than the subsequent trials being complete 
in 10h compared to the 14h to reach completion with the recycled particles. However, the consistency of 
the reactivity of the recycled particles suggests that no loss in reactivity is observed. However, the 
evidence at hand indicates that the catalytic activity of CuBTC towards NO generation is dependent upon 
the availability of substrates. As such in a biological system where the supply of RSNOs is continuously 
maintained the lifetime of NO release from the material is only subject to the structural integrity of the 
catalyst.  
Table 1. CuBTC turnover with various equilavents of CysNO substrate 
Conditions Catalyst Turnovera 
CysNO:MOF-CuII(2:1) 1.9±0.1 
CysNO:MOF-CuII (10:1) 9.8±0.3 
CysNO:MOF-CuII (15:1) 15.0±0.1 
CysNO:MOF-CuIIRecycling 8.0±0.3 




Catalyst Structural Stability Assessment. In order to verify that the observed reactivity towards NO 
generation is truly an artifact of CuBTC and not solvated Cu2+ ions resulting from the degradation of the 
framework analogous NO generation experiments were performed using the copper salt, CuCl2 as the 
catalyst. In each experiment the amount of Cu2+ added to the reaction is equivalent to the total amount of 
Cu incorporated as CuBTC. Using this approach if all the framework was to fully degrade releasing 
solvated Cu2+ ions we should see similar reactivity. Towards this end the reactivity of CysNO in the 
presence of solvated Cu2+ ions listed in Table 2 is increased by an order of magnitude from 9.64 ± 0.26nM 
s-1 with CuBTC to 161 ± 18 nM s-1 when CuCl2 is used as the catalyst. The slow reactivity of CuBTC 
catalyst compared to solvated Cu2+ ions is attributed to the accessibility of the active sites and the 
heterogeneity of the MOF catalyst. The active sites in CuBTC are embedded within the framework matrix 
requiring diffusion of the substrates through the pore space for accessibility. Furthermore, as a 
heterogeneous catalysts an addition energetic requirement is posed by requiring the adsorption of 
substrates from the solution faces onto the heterogonous catalyst.35 Taken together these results strongly 
suggest that MOF bound Cu2+ ions are responsible for the observed reactivity.    
In order to verify the structural integrity of CuBTC particles following reaction with CysNO the particles 
were filtered post reaction from the solution for analysis via pXRD and ATR-IR and the filtrate was 
assessed by elemental analysis for copper content. After removal from the reaction solution the MOF 
particles were rinsed and subsequently activated. Upon activation the MOF particles underwent the 
characteristic color change for CuBTC from tourquoise (unactivated) to dark blue (activated), which is 
indicative of a structurally intact framework.31 The resultant crystallinity of the particles was evaluated by 
pXRD and compared to the unreacted particles shown in Figure 5. Identical diffraction patterns indicate 
that the structural integrity of the framework remains unaffected after reaction with CysNO.  
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Figure 5. Powder XRD pattern of CuBTC as fresh particles (bottom) and after reaction with CysNO (top)    
In a separate study to verify that small amounts of Cu2+ ions were not leached into solution and may 
contribute to the observed NO generation the reaction filtrate was evaluated for copper content using ICP-
OES via EPA method 200.8. The residual copper in the solution was found to be 0.1 ± 0.08% of the total 
MOF copper content. A separate NO release study aimed at assessing the contribution of the Cu2+ ions 
that are present in solution towards the observed NO generation was established. As shown in Figure 6, 
an aliquot of CuCl2 equivalent to the concentration of leached ions determined by elemental analysis was 
added to the reaction solution containing CysNO. The addition of this low concentration of Cu2+ ions was 
found to not increase the rate of NO generation when compared to blank control measurements. As a 






Figure 6. Investigation of contribution of solution based Cu2+ ions towards the generation of NO from 
CysNO.  
Investigation of Substrate Structure on the Reactivity of the Material. The successful demonstration of 
CuBTC as a NO catalyst prompts further investigation into the selectivity of the material with alternative 
RSNOs. Investigations of MOFs as materials for separations applications have made note of the 
importance of the pore size for effectively separating substrates of various molecular sizes and the 
electrostatic environment within the pore channels facilitates interaction with substrates via van der waals 
interactions and is effective for use as a chromatographic column even effective for enantiomeric 
species.7,9,36 The effect of substrate structure on reactivity with CuBTC was evaluated by selecting seven 
RSNO substrates, shown in Figure 7, based on subtle variations in molecular size and polarity. In order to 
compare only the effects of substrate size RSNO pairs were selected that differed only by the addition of a 
carbon atom in the molecular backbone and are (TgaNO)/(MPANO) and (HcysNO)/CysNO. Investigation 
of the effects of polarity is based on a 2 carbon backbone with substituted amino (CysamNO), hydroxyl 
(MeNO), and carboxyl (TGANO) terminal functional groups including; secondly the effects of adding an 
additional functionality, either an amino group (MPANO/CysNO) or a methyl group (TGANO/TLANO), 
to the carbon back bone were assessed. A summary of the rates of NO generation from each substrate 




Table 2. Rate of NO Generation from various RSNOs 
RSNO Blank (nM s-1) CuBTC (nM s-1) CuCl2 (nM s-1)  
CysNO 2.55 ± 0.21 10.4 ± 0.2 161 ± 18 
CysamNO 2.23 ± 0.30 21.3 ± 0.9 231 ± 12 
HcysNO 3.22 ± 0.19 3.10 ± 0.94 157 ± 12 
MPANO 2.80 ± 0.11 4.56 ± 0.68 214 ± 19 
MeNO 1.60 ± 0.27 11.1 ± 1.6 264 ± 23 
TGANO 2.30 ± 0.60 20.1 ± 1.1 515 ± 73 
TLANO 1.23 ± 0.10 26.1 ± 1.7 441 ± 45 
All rates are reported at 25 °C.  Data points were run in triplicate and reported to the 95% confidence 
interval.  
 
Figure 7. Molecular structures of S-nitrosothiol substrates probed for structure/reactivity studies  
The reactivity of CuBTC with each substrate was evaluated based on the rate of NO generation. The 
reactivity of CuBTC based on the substrate size was evaluated with structurally analogous substrate pairs, 
TGANO/MPANO and CysNO/HcysNO, which differed only by the addition of a single carbon atom in 
the molecular backbone. From each pair the smaller substrate, TGANO and CysNO were found to be 
more reactive than their larger analouges. The use of CuBTC resulted in a 5 fold increase in the rate of 
NO generation for CysNO compared to the uncatalyzed reaction, however the rate for HcysNO remained 
unchanged comparatively. Interestingly, the reactivity of CysNO and HcysNO with solvated Cu2+ ions are 
equivalent at 161 ± 18 nM s-1 and 157 ± 12 nM s-1, respectively. Where CysNO/HcysNO is concerned 




a lack of activity with CuBTC it is reasonable to conclude that the increased size of HcysNO precludes 
interaction with the active sites of the MOF catalyst and accounts for the lack of reactivity. Based on 
these findings it is reasonable to expect that the larger MPANO substrate would exhibit slower rate of 
reactivity compared to TGANO, however if the substrate size is the sole determining factor in reactivity 
of CuBTC then it would also be reasonable to expect that the reactivity of the 3-carbon chain MPANO 
would be on par with the 3 carbon CysNO substrate. However based on the reactivity data the rate of NO 
generation with MPANO is merely doubled compared to the 5-fold increase in rate observed for CysNO 
indicating that the addition of amino functional group plays a contributing role in substrate reactivity with 
CuBTC.  
The interior pore environment of CuBTC is hydrophilic, demonstrated by the facile adsorption of water 
molecules into the pore space. Increasing the polarity of CysNO with the inclusion of the amino groups 
therefore increases the affinity of the framework for adsorption into MOF pores and accessibility to the 
Cu active sites, compared to the similarly sized MPANO. To further support the influence of substrate 
polarity on the reactivity with CuBTC as a catalyst we can consider the 2 carbon chain pair TGANO and 
TLANO which differ by the inclusion of a methyl group on the carbon backbone of TLANO. According 
to our previous findings it is reasonable to expect that the reactivity of TLANO would be diminished 
compared to TGANO due to the inclusion the nonpolar functional group. However, following reaction 
with CuBTC the rate of NO generation from TLANO at 26.1 ± 1.7 nM s-1 is greater than that of TGANO 
at 20.1 ± 1.1 nM s-1. These seemingly contradictory results can be explained by the small molecular size 
of TLANO which can be easily accommodated in the pore space of the MOF and the inclusion of the 
hydrophobic methyl group diminishes the affinity of the framework for the substrate allowing for more 
facile diffusion of the substrate to the active sites.      
To examine the extent of electronic influences on the reactivity of the RSNOs with the MOF catalyst, 
RSNOs were selected with diverse terminal electron withdrawing R groups on the β carbon:  (i) amino 




rate of NO generation from MeNO 11.1 ± 1.6 nM s-1 is the slowest whereas the rate for CysamNO  and 
TGANO were doubled at  21.3 ± 0.9 nM s-1 and 20.1 ± 1.1 nM s-1, respectively. These differences in 
substrate reactivity when a MOF catalyst is utilized can be explained by the affinity of the ancillary 
functional groups with the framework walls, where increasing affinity results in decreased rates of NO 
generation.  
Alternative Metal Ions as RSNO Catalysts. To verify that the Cu metal ions are in fact the active sites and 
the resulting NO is not an artifact of host/guest chemistry an iron based MOF with similar pore 
dimensions was selected. The use of an Fe based MOF is ideal for evaluating the contribution of the metal 
center as the active site since Fe3+ is known to have limited success towards the decomposition of RSNOs 
resulting in the liberation of NO.29 Under analogous conditions to NO release measurements with 
CuBTC, the Fe-MOF Fe(BDC)17 was added to the reaction solution containing CysNO as the substrate. 
After a 15h period the generated NO in the presence of Fe(BDC) was equivalent to the results observed 
for the autocatalytic decomposition of CysNO, shown in Figure 8. Surprisingly however literature reports 
indicate that Fe(BDC) is capable of driving thiol oxidation reactions suggesting that accessibility of the 
metal centers is not the reason for the lack of observed activity. Taken together these results confirm the 
importance of the Cu active site for catalyzing the release of NO.       
The established redox mechanism for the decomposition of RSNOs using homogenous Cu2+ ions suggest 
that the Cu1+ species interacts with the thiol component and the ancillary functional groups forming a 
cyclic intermediate resulting in homolytic cleavage of the S-N bond to generate the thiyl radical, NO, and 
Cu2+.29 In contrast, the active site of Cu3(BTC)2 precludes bidentate coordination of the ligand based on 
the availability of only one open coordination site around the copper ion. Furthermore, it is unclear at this 
time whether or not MOF catalysts with the metal centers as active sites are capable of undergoing redox 
behavior without incurring structural damage. Instead it has been established that the active Cu2+ metal 




of the material.37  With these two conflicting mechanisms supplied for the catalyst and thiol it begs the 
question of which pathway the reaction between CuBTC and RSNOs proceeds.   
 
 
Figure 8.Reactivity of FeBDC towards catalyzing NO generation from CysNO 
Recent work outlining the interactions of RSNO substrates with Lewis acids indicates that the RSNO 
resonance forms dictate the types of interactions that they may have with catalysts as well as the resulting 
products from S-N cleavage. The S, N, and O atoms of the S-nitroso group are each able to serve as a 
Lewis base and coordinate to the acid Cu2+ site. The interaction of a Lewis acid with the RSNO results in 
the generation of NO radical through coordination of the nitrogen atom.37 Coordination of the nitrogen 
atom to the acidic Cu2+ active site of CuBTC would then result in the cleavage of the S-N bond while 
forming a nitrosyl as an intermediate. Cleavage of the S-N bond will likely be facilitated by substituents 
which can effectively stabilize the thiyl radical species and are most likely to be electron donating 
substituents. The increase in the reactivity of RSNOs with CuBTC as a catalyst directly corresponded to 
the presence of electron donating groups in proximity to exert inductive effects on the S-nitroso group.  
To probe the reactivity of RSNOs with a Lewis acid catalyst aluminum was selected as the metal ion 
catalyst due to its redox inaccessible nature and well known activity as a Lewis acid activity. To probe the 
"#!
effects of a known Lewis acid the aluminum salt AlCl3 was used to investigate the reactivity of Al3+ ions 
with RSNOs.  As shown in Figure 9a solvated Al3+ ions catalyze the decomposition of over a 5 hour 
period before depleting the available substrate in comparison to the uncatalyzed reactivity of the material.  
These results are the first report of the feasibility of using Al3+ as a catalyst for the generation of NO from 
RSNOs. In comparison to solvated Cu2+ ions which catalyze RSNO decomposition via a redox pathway, 
Al3+ reactivity with RSNOs proceeding via a Lewis acid pathway results in a significant decrease in the 
reaction rate.  
To further probe the feasibility of using Al3+ ions as metal ions for the liberation of NO from RSNOs the 
MOF the aluminum MOF Al(BDC) was investiged as an NO catalyst. The reaction of Al(BDC) with 
CysNO shown in Figure 9b, results in an NO release profile that is reminiscent of CuBTC, however the 
reaction rate is reduced by half taking 20 hours to reach completion.  The slowed reactivity of Al(BDC) 
compared to CuBTC is consistent with the more facile reaction of Cu2+ ions with RSNOs compared to 
Al3+. However this demonstration of the feasibility of using Al3+ ions as RSNO catalysts as well as the 







In this work the first demonstration of a robust solid state Cu catalyst for the generation of NO is 
presented. Increased interest in the use of MOFs in in biomedicine has spurred the development of MOF 
drug delivery vehicles and biocatalysts. In this work a MOF is demonstrated for the first time to catalyze 
the generation of a bioactive molecule, NO, with the ultimate intention of use in a therapeutic setting. 
However, the Cu-MOF catalyst used in this work is subject to degradation in an aqueous environment 
ultimately precluding the use of this framework in a biomedical application for extended use. Notably, 
from this proof of principle work information regarding the selectivity of MOFs with substrates was 
determined based on size and electrostatic constraints. Furthermore, the importance of Cu atoms as the 
catalytic center was established by probing the reactivity of alternative MOFs with Al3+ and Fe3+ metal 
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The versatile chemical and physical properties of metal organic frameworks (MOFs) have made them 
unique platforms for the design of biomimetic catalysts, but with only limited success to date due to 
instability of the MOFs employed in physiological environments. By adjusting the metal ligand acid base 
pairing a Cu-MOF with aqueous stability can be prepared using 1,3,5-Benzene-tris-triazole as the linking 
ligand to create CuBTTri. CuBTTri exhibited structural integrity in aqueous environments, including 
phosphate buffered saline (76 h, pH 7.4, 37 °C), cell media used for in vitro testing (76 h, pH 7.4, 37 °C), 
and fresh citrated whole blood (30 min, pH 7.4, 37 °C). Subsequently, CuBTTri was evaluated for 
catalytic generation of the bioactive agent nitric oxide (NO) from endogenous sources, S-nitrosothiols 
(RSNOs). The application of CuBTTri for use in polymeric medical devices was explored through the 
formation of a composite CuBTTri-poly by blending CuBTTri into biomedical grade polyurethane 
matrices. Once prepared, the CuBTTri-poly material retained the catalytic function towards the generation 
of NO with tunable release kinetics proportional to the total content of CuBTTri embedded into the 
polymeric material with a surface flux corresponding to the therapeutic range of 1-100 nM s-1 cm-2, which 
was maintained even following exposure to blood.       
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The development of any material for a biological application requires that the material fulfills the 
intended function without resulting in any adverse effects. While there are many proposed applications 
for the use of MOFs in biomedicine, to date the development of bioMOFs remains limited by the 
susceptibility towards degradation in a biological environment.1,2 While degradation may not be a limiting 
factor for materials targeted as drug delivery vehicles that need to be cleared after releasing their 
payloads, the use of MOFs as bioinspired catalysts requires that they be resistant towards degradation in 
the biological environment. The two primary components of the assembly of a MOF that dictate the 
stability of the material are the lattice type and the metal ligand interactions. While in many cases the 
resulting lattice is an artifact of synthetic conditions and the coordination cluster, the resulting metal-
ligand interactions can be easily tuned based on the type of metal and ligand used in the preparation of the 
material. As a result the crucial challenge in the development of a bioMOF NO catalysts is the 
functionalization with a suitable biocompatible ligand while preserving catalytic function of the MOF. 
The formation of a MOF is first and foremost dependent upon the type of coordination complex that 
forms between the metal ion and the ligand. This complex then proceeds to function as a secondary 
building unit (SBU) which is repeated throughout the MOF as a the nodes of the crystalline structure.3-5 
As a result the stability of the SBU assembly dictates the overall stability of the framework. As a 
coordination complex the stability is dictated by the same rules that apply to small molecule complexes 
including hard soft Lewis acid base theory. The use of carboxyl based ligands are amongst the favorites 
for the formation of MOFs, however the stability of the complexes formed are known to be subject to 
decomposition in air, as well as aqueous environments.6,7 As a result the key factor towards the 
development of robust water stable MOFs relies in the appropriate selection of an alternative ligands.  
A promising class of ligands for use in the construction of water stable MOFs are 5 member aromatic 




complexes with azole based ligands is well known to have a tendency to form insoluble salts, it wasn’t 
until recently that exploration of MOFs with azole based ligands became of interest. Tetrazoles are 
commonly used as analogues to carboxylic acid ligands due to their very similar pKa values of 4.5. The 
preparation of Cu-MOFs with tetrazole based ligands results in porous 3D frameworks, yet the stability 
towards aqueous environments remains unimproved compared to carboxyl based MOFs.10   Imidazole is 
an alternative azole based ligand known to construct Zn based frameworks with exceptional chemical and 
thermal stability.11 However, the construction of Cu-imidazole MOFs results in frameworks which readily 
degrade in an aqueous environment. The reduced stability of Cu2+ ions with both imidazole and tetrazole 
based ligands is attributed to poor acid/base pairing. Cu2+ is considered a borderline ion in the hard/soft 
Lewis acid/base activity series whereas imidazole is strongly basic and tetrazole is an acidic species. 
Therefore a suitable ligand for the generation of a robust Cu-MOF would have a pKa value between 
tetrazole at 4.5 and imidazole at 14.5, resulting in the selection of triazole (pKa =9.2) ligands as suitable 
candidates for preparation of MOFs with aqueous stability.  
Examination of literature reports for a reported framework which fits the criteria of a Cu-triazole MOF 
with coordinatively unsaturated metal centers revealed a report from the Long group of a water-stable Cu-
MOF coordinated by 1,3,5-benzenetristriazole ligands referred to here on as CuBTTri (Figure 1).12 While 
there are numerous reports of CuBTTri as an excellent material for the adsorption of CO213,14 our aim in 
the present studies was to broaden the scope of CuBTTri applicability for use as a biocatalyst. Herein, the 
potential of CuBTTri as a MOF NO catalyst with the RSNO substrate, S-nitrosocysteamine (CysamNO) 
according to equation (2) is evaluated in conjunction with structural stability measurements via pXRD 
following reaction with CysamNO and in mediums routinely used for in vitro and in vivo experiments, 
including phosphate buffered saline (PBS), cell media, and whole blood. Subsequently, the development 
of a composite material with CuBTTri blended into biomedical polyurethane resulted in the capacity for 




here we demonstrate the capacity for tuning the NO surface flux of the material to lie within the 
physiologically relevant range.   
 
Figure 1. MOF biocatalyst, CuBTTri, for the catalytic generation of nitric oxide from bioavailable 
substrates. (A) Synthesis of CuBTTri, (B) Reactivity of CuBTTri with S-nitrosocysteamine (CysamNO), 
(C) Comparison of Total NO release rates between CuBTTri, uncatalyzed CysamNO decomposition, and 
solvated Cu2+ ions. 
 
Experimental Methods 
Materials. All reagents and solvents were purchased from commercial vendors and used without further 
purification unless otherwise noted. 1,3,5-tribromobenzene (98%), trimethylsilyl azide (94%), 
(trimethylsilyl)acetylene (98%), and diethylamine (99%) were purchased from Alfa Aesar.  Cysteamine 
hydrochloride (Fluka, 99%), ethylenediaminetetraacetic acid (EDTA) disodium salt (EMD, 99%), copper 
iodide (Sigma, 99.5%), bis(triphenylphosphine) palladium(II) chloride (TCI America, 98%), copper 
chloride dihydrate (EMD, 99%), potassium carbonate (Fisher, 99%), and t-butyl nitrite (Sigma, 90%). 
Ultra high purity N2 and O2 gases were supplied by Airgas (Denver, Colorado) and solvents PBS tablets 
(Calbiochem) and Endothelial cell Media MCMD151 (Invitrogen) for the NOA measurements. Water 




CuBTTri Synthesis: CuBTTri-H2O.H3[(Cu4Cl)3(BTTri)8(H2O)12]•72H2O.1  1,3,5-tris(1H-1,2,3-triazol-5-
yl)benzene (225mg) synthesized according to previously reported methods,[24] was dissolved in 30 mL 
DMF in a 120 mL vial.  Triazole solution was adjusted to pH 4 with a dilute HCl solution.  CuCl2•2H2O 
(383 mg) was dissolved in 10 mL DMF and added to triazole solution.  Vial was placed in oven at 100 °C 
for 72 hours followed by the reaction solution being kept at room temperature for 1 week. Resulting 
purple powder was centrifuged and washed with DMF 3 times.  The percent yield of as synthesized 
CuBTTri-DMF was 75%. The powder was then placed in a Teflon lined Parr bomb along with 5 mL 
deionized water and heated in oven for 24 hours at 100 °C.  Purple powder was again centrifuged, washed 
with water and allowed to air-dry in hood for several days.  
Preparation of CuBTTri Films. Composite materials were prepared by dissolving 200 mg of Tygon 
polymer in 2 mL of THF. To the solvated polymer CuBTTri was added at 1 wt% (mg) and 4 wt% (mg). 
The CuBTTri polymer was cast into circular molds (radius of 2  mm)  and allowed to cure under ambient 
conditions for 48 hours. For NO release experiments the films were punched into 4 mm disks. Leaching 
analysis for each film was determined by the copper content found in the reaction solution following each 
experiment.   
Preparation of RSNOs. A fresh stock solution of each RSNO was prepared in situ prior to each reaction. 
In brief, 0.05 M cysteamine hydrochloride was nitrosated with excess t-butyl nitrite. After reacting for 10 
minutes under agitation in an ice bath, the concentration of the red CysamNO solution was determined by 
UV-vis spectroscopy using characteristic absorption bands  for RSNOs at 335 nm (ε = 793 M-1 cm-1)  and 
545 nm (ε = 15 M-1 cm-1).   
Nitric Oxide Release Measurements. Nitric oxide generation was recorded in real time using a 
chemiluminescence based GE nitric oxide analyzer. To the NOA sampling vessel, 2 mL of PBS was 
added, where the PBS was treated with Chelex resin to remove trace amounts of Cu2+ ions and the pH 




directly to the PBS solution and purged continuously for the duration of the experiment with ultrapure 
nitrogen gas. An aliquot of CysamNO was introduced directly into the solution in a gas tight Hamilton 
syringe through the side injection port of the NOA vessel. NO release was recorded in 1 second intervals 
as parts per billion with a gas sampling rate of 200mL/min. Raw data was processed using Microsoft 
Excel 2010.        
The solution was maintained in a nitrogen atmosphere with bubbling of 16mL/min N2 directly into the 
solution and flow gas introduced at 184mL/min into the remaining headspace, the system was 
continuously sampled under vacuum at 200mL/min.  
SEM imaging and EDX analysis of CuBTTri-Poly Films. Using a JEOL JSM-6500F (FSEM) with an 
accelerating voltage of 20.0 kV and a working distance of 10.1 mm. Images were taken at magnification 
values of 500x and 5,000x and processed for copper distribution using EDX spectroscopy. The EDX 
spectrum was collected at an accelerating voltage of 20.0 kV   at 130X magnification. All data was 
processed using Thermo NSS Release candidate 7 software.  
Copper Leaching Studies.  Inductively Coupled Plasma characterization was conducted on a Perkin Elmer 
Sciex DRC II . Table S1 displays pertinent information to ICP studies.  A representative procedure is as 
follows: PBS (3mL) was added to a 20mL vial containing CuBTTri-H2O (5 mg).  To this mixture 300µL 
S-nitrosocysteamine was added.  The vial was placed in a preheated sand bath at 37°C for 12 hours.  The 
mixture was then centrifuged and the supernatant was filtered through a syringe equipped with a 0.2µm 
filter.  Filtered solutions were then sent for Cu analysis.   
Statistical Analysis. Statistical t-tests were performed on each data set to determine statistical differences 
at the 95% confidence interval.  
Results and Discussion 
Heterogeneous vs Homogenous Catalyzed Reaction: Assessment of MOF Structural Stability. The 




of the material as a catalyst. Towards this end, we assessed the structural integrity of the catalyst based on 
the retained crystallinity of the material by powder X-ray diffraction and by elemental analysis of the 
post-reaction filtrate for residual Cu2+ ions.  Evaluation of the soaking solution for Cu2+ content following 
the reaction indicated that 0.04 ± 0.01 % of the available Cu2+ ions from the initial CuBTTri added to the 
reaction is accounted for in the filtered reaction solution. At this concentration of Cu2+ ions, the rate of 
NO release from CysamNO is the same as that of the uncatalyzed reaction within experimental error, 
indicating that the observed increase in the rate of NO release is associated with Cu2+ ions bound in the 
CuBTTri framework. Assessment of MOFs using pXRD is an established method for indicating the 
structural integrity of the material based on the capacity of the material to retain its original crystallinity. 
In comparison to the parent diffraction pattern, when CuBTTri particles were immersed in PBS at 37 °C 
for 72 h, the CuBTTri particles post reaction with CysamNO (0.5 mM in PBS) retained their original 
diffraction pattern, as shown in Figure 2c. Since, the assembly of MOFs require the use of specific 
reaction conditions to a achieve a particular topology, the dissolution of the framework and subsequent 
recrystallization is not likely to result. Hence, the implied conclusion is that the framework is retaining 
heterogeneous character over the course of the reaction. In short, tunable release kinetics of a therapeutic 
agent from an endogenous source plus unprecedented stability of a MOF in PBS solution makes CuBTTri 
an excellent candidate for exploration in biotherapeutic applications. 
Stability of CuBTTri under in vitro and in vivo conditions. The integration of MOFs in a biological setting 
further requires the evaluation of CuBTTri stability in cell media solutions used for in vitro testing and, 
most importantly, in body fluids. Hence, the crystallinity of CuBTTri was assessed after immersion in 
endothelial cell media maintained at pH 7.4 by a 5% CO2 atmosphere for 72 h and in a separate 
experiment, following brief exposure (30 min) to fresh citrated whole blood the crystallinity was 
assessed. The representative diffraction patterns (Figure 2c) indicate that the structural integrity of the 
material was preserved.  This is an important result because minimal biodegradation of CuBTTri has the 




in vitro and in vivo testing remains to be done to determine any toxicity associated with CuBTTri, Cu 
remains an essential trace element in physiology rendering the body capable of uptake and clearance of 
MOF degradation products.15  
Catalytic Activity of CuBTTri. The catalytic activity of CuBTTri towards the generation of NO when 
reacted with CysamNO in PBS was monitored in situ using chemiluminescence detection. The reactivity 
of CuBTTri was evaluated by comparing the rate of NO generation in the absence of a catalyst and with 
solvated Cu2+ ions as controls (Figure 1C). The average rate of NO generation in PBS at 25 °C when 
catalyzed by CuBTTri is 22.8 ± 2.1 nM s-1 and is an order of magnitude greater than the uncatalyzed 
reaction at 2.9 ± 0.6 nM s-1 (Table 1). Comparatively, in the presence of solvated Cu2+ ions (equation 1) 
the rate of the reaction increases an additional order of magnitude to 333.0 ± 5.1 nM s-1 when compared to 
CuBTTri. These results are consistent with the previous reports of the reactivity of solvated Cu2+ catalysts 
with RSNOs.16 Specifically, Cu-MOF catalysts with RSNOs have shown the same reactivity trendior17.  
We further investigated the influence of the catalyst content with regard to substrate concentration on the 
rate of NO release (Figure 2). First, the influence of substrate concentration on the rate of NO generation 
was explored when the reaction content of the catalyst remained consistent as shown in Figure 2a. In 
these experiments, the rate of the reaction increased linearly as the concentration of the substrate was 
increased; however, the reaction with respect to CysamNO proceeded via zero-order reaction kinetics. 
Interestingly, in each case the amount of NO recovered was equal to 50% of the substrate conversion, 
leading to total turnover numbers ranging between 1.06 ± 0.04 to 3.90 ± 0.16, shown in Table 1. Notably, 
even when the reaction content of CuBTTri was in excess of the substrate, the conversion to NO remained 
consistent at 50%. When an additional aliquot of RSNO substrate was added, NO generation continued 
until equilibrium was reached again. As shown in Figure 2b, as the catalyst content in the reaction was 
increased, there was a linear correlation with the rate of NO release with second-order kinetics being 
followed. Taken together, these results indicate that CuBTTri successfully executes the role of a catalyst 




Critical challenges in the development of NO releasing therapeutic materials are often due the difficultly 
in tuning NO delivery kinetics for therapeutic effectiveness. Additionally, it is critical to overcome the 
finite amounts of NO that can be incorporated into the material, which currently limit the active lifetime 
of the material.18 However, the catalytic activity of CuBTTri exhibited herein towards NO generation is 
the highest reported delivery of NO to date at 10 mmol NO per g MOF, even exceeding highest previous 
NO-MOFs by the Morris group at 7mmol/g.19 In addition, the NO generation capacity demonstrated 
herein is actually a lower, not an upper limit as is the case with traditional NO donor based materials, 
which rely on an incorporated reservoir of NO donors. This is true due to renewable sources of RSNO 
provided in the blood stream. When using the present catalyst,  kinetic control over the amount of NO 
generated is possible via control of the catalyst content facilitating tunable dosages of NO for therapeutic 
applications and despite the likely fluctuation of RSNOs in the blood stream.   
Table 1. Summary of rate of NO generationa 
Catalystb  CysamNO 
(mM) 




None 0.50 n/a 2.88 ± 0.58 n/a 
CuBTTri 0.25 2:1 17.3 ± 2.54 1.06 ± 0.04 
CuBTTri 0.50 4:1 22.8 ± 2.08 1.90 ± 0.16 
CuBTTri 1.0 8:1 24.2 ± 2.32 3.90 ± 0.16 
CuCl2 0.50 4:1 333 ± 5.10 1.43 ± 0.03 
aAll experiments performed in PBS (2mL, pH 7.4, 25 °C) at n=3 and reported at 95% confidence interval 






Figure 2. (a) Rate of NO generation from CysamNO (0.5mM) in PBS (2mL) catalyzed by CuBTTri at 25 
°C. (b) Rate of NO generation from CysamNO catalyzed by CuBTTri (0.2mg) in PBS (2mL) at 25 °C. 
Values (n=3) and standard deviations reported to the 95% confidence interval. (c) Powder X-ray 
diffraction patterns of parent CuBTTri particles compared with CuBTTri particles immersed in PBS (37 
°C, pH 7.4); 5mM CysamNO in PBS (37 °C, pH 7.4); Endothelial cell media (37 °C, pH 7.4 maintained 
with 5% CO2 buffer); Fresh citrated whole blood (37 °C, pH 7.4). 
 
Composite CuBTTri Biomedical Grade Polyurethanes. The administration of MOFs in biomedicine is 
achieved either through bulk administration in the blood stream or through the formation of composite 
materials. Composite materials are particularly advantageous in that they have the flexibility to be 
incorporated into a wide range of existing polymeric medical devices. Moreover, the immobilization in 
device matrices is expected to facilitate the site-localized delivery of the therapeutic. The high reactivity 
of NO necessitates site specific generation at the intended physiological site. Hence, we explored the 
activity of CuBTTri towards catalytic NO generation once embedded into a matrix of biomedical grade 
polyurethane. CuBTTri-poly films were prepared by incorporating CuBTTri at 1 or 4 wt% into a solution 




Examination of CuBTTri-polymer by SEM is shown in Figure 3, indicating that there are MOF particles 
on the surface the material, but that the majority of MOF particles remain embedded within the polymeric 
matrix. Dispersion of the CuBTTri particles throughout the polymeric matrix was assessed by analyzing 
the material for Cu content using SEM analysis accompanying energy dispersive X-ray analysis. As 
shown in Figure 3b, there is a relatively even dispersion of Cu atoms throughout the material, indicating 
that the CuBTTri particles are embedded within the polymer matrix.   
 
Figure 3. (a) SEM of CuBTTri- poly films at 1000x magnification, (b) SEM-EDX mapping of Cu content 
in CuBTTr-poly films at 1000x magnification, and (c) Total NO release from CysamNO, CuBTTri, 4% 
CuBTTri-poly film, 1% CuBTTri-poly film. Values (n=3) and standard deviations reported to the 95% 
confidence interval.  
Catalytic Activity of CuBTTri-poly materials. The catalytic generation of CuBTTri once embedded into 
the polymeric matrix was evaluated by reacting 1 and 4 wt% CuBTTri-polymeric materials with 
CysamNO in PBS. To deduce the effects of encapsulation on the reactivity of CuBTTri, we compared the 
rate of NO generation between the free CuBTTri particles and the 4% CuBTTri films using an equivalent 
amount of CuBTTri (0.5 µmol Cu2+) in each experiment.  The results show that the rate of NO release is 




reaction to that observed with the non-embedded particles. The slowed reactivity of the polymer-
encapsulated CuBTTri is the expected result of diffusion limitations of the substrate towards reaching the 
CuBTTri active sites.  Reducing the total amount of CuBTTri incorporated into the polymeric matrix 
further reduces the rate of NO generation from CysamNO, which is consistent with our findings that 
kinetic control over the amount of NO generated is based on the availability of the catalyst, shown in 
Figure 3c. Following the reaction of the composite material with CysamNO, the reaction solution was 
evaluated by ICP-MS for Cu content in order to establish the extent of CuBTTri leaching from the 
polymer membrane. For both the 1% and 4% films, ≤0.47 ± 0.03% of the available Cu2+ ions were found 
in solution following removal of the CuBTTri-poly material.   
Site Localized Delivery of Therapeutic NO Dosages. The in vivo effects of NO are concentration 
dependent resulting in protective and proliferative effects at low concentrations (0.1-10 nM), and 
cytotoxic effects at high concentrations (100 nM), requiring careful tuning of NO release properties to 
exhibit intended effects.20 Since the rate of NO generation using CuBTTri is dependent upon the amount 
of available catalyst in the material, CuBTTri thereby provides a unique handle for mediating the surface 
flux of NO in CuBTTri-poly materials. The average surface fluxes from the 4% and 1% CuBTTri films 
are 1.87 ± 0.08 nM s-1 cm-1 and 0.77 ± 0.06 nM s-1 cm-1, respectively, falling within the protective and 
proliferative therapeutic range.21,22 Furthermore, we explored the effects of immersing CuBTTri-poly 
material in fresh citrated whole blood (37 °C, 30 min) on the reactivity of the material towards NO 
generation from CysamNO. Following immersion in blood, the CuBTTri-poly film was thoroughly rinsed 
with water and subsequently reacted with CysamNO in PBS to evaluate the materials capacity for 
generating NO. The resulting NO surface flux of the blood exposed CuBTTri-poly film (0.75 ± 0.08 nM 
s-1 cm-1) remained consistent with the flux observed for the non-exposed film (0.77 ± 0.06 nM s-1 cm-1). 
These results provide the first demonstration that a MOF biocatalyst can retain its therapeutic action 






The use of a triazole based ligand CuBTTri remains structurally intact in aqueous mediums including 
biological fluids. Contrary to previous inceptions of drug delivery vehicles, the use of an embedded 
catalyst liberates the materials dependence on the limited reservoirs of bioactive by relying on substrates 
(herein, RSNOs) supplied continuously in the physiological environment. The result is a resulting in a 
self-sustaining, therapeutic delivery system. In addition, tunable NO release kinetics were demonstrated 
based on the content of catalyst embedded into polymeric therapeutic materials. Most importantly, for the 
sustained use of the material, CuBTTri remains structurally intact in aqueous mediums including 
biological fluids, including whole blood, while retaining catalytic activity of the material. While rigorous 
in vitro and in vivo testing remains to be done to examine the full extent of the potential of CuBTTri in a 
therapeutic setting, this is the first report of a MOF which can catalytically generate a bioactive molecule 
from an endogenous source on the surface of a polymeric film with the capacity for tunable release 
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The preparation of MOF composite materials as blends incorporated into organic polymeric matrices is 
commonly referred to as the preparation of MOF mixed matrix membranes (MMMs).1-4 The construction 
of MMMs are routinely used for liquid and gas phase separations of small molecules as well as use as 
immobilizing MOFs for catalytic applications. However, the development of MOFs as MMMs is 
routinely on a rather small scale when materials are cast from molds on laboratory bench tops. For 
commercialization purposes it is essential to investigate the capacity for MOFs to withstand commercial 
material manufacturing methods often involving extrusion. The critical requirement for MOF 
incorporation as a blended material is maintained structural stability after processing. This work aims to 
investigate the influence of commercial manufacturing processes on the structural and chemical stability 
of MOFs for the development of blended MOF-polymer composite materials.   
Introduction 
The integration of MOFs in biomedicine necessitates the use of a secondary support so as to provide site 
specific activity of the frameworks. Towards this end MOF composite materials can be formulated by 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!
4! The work presented herein is published in the Journal of Materials Chemistry B with Melissa M. 
Reynolds as a joint author and is used with permission. The body of work presented here was assembled 





incorporating MOFs as dispersions in polymeric materials, commonly referred to as mixed matrix 
membranes.1,5 The controlled integration of MOFs to form composite materials with either inorganic or 
organic substrates is advantageous for the development of functional materials which can complement the 
merits and mitigate shortcomings of existing material types thereby exceeding the functional capacity of 
the individual components. Polymeric materials are commonly used in the construction of biomedical 
devices and as such present an ideal substrate for investigating the feasibility of constructing MOF 
composite materials geared towards therapeutic applications.  For the successful preparation of composite 
MOF biomaterials manufacturing must occur without significant modification to existing processes used 
in device construction.  In this respect a critical test for the use of MOFs in device fabrication is their 
process ability into functional devices.  
However the key requirement for the preparation of MOF composite materials is after fabrication of the 
material it is essential that the MOF remains structurally and chemically unaffected without 
compromising functionality. MMM’s prepared on small laboratory scales utilize solvents based casting to 
shape materials into useable forms without impairing the MOF. However commercial manufacturing 
processes utilize heat and pressure to mold materials into desired shapes and sizes. Given the reported 
robustness of MOF capable of withstanding temperatures up to 500 °C and insoluble in organic solvents it 
is hypothesized that MOFs will be capable of withstanding manufacturing conditions. As such, the 
incorporation of structurally robust and catalytically active MOF particles in the matrix of biomedical 
devices has the potential to mediate negative interfacial material responses including reducing instances 
of surface biofouling and even mitigating proliferative effects towards the regeneration of healthy 
tissues.6      
This work aims to investigate the influence of commercial manufacturing processes on the structural and 
chemical stability of MOFs for the development of blended MOF-polymer composite materials.  Towards 
this end the structural integrity of CuBTC following extrusion with biomedical grade polyurethane into 




material with the parent CuBTC particles by powder X-ray diffraction (pXRD). Subsequently the relative 
dispersion of the particles within the blended composite was assessed SEM imaging coupled with 
elemental selective EDX analysis. The reactivity of CuBTC-poly material was evaluated for the capacity 
to catalytically generate NO from RSNO substrates.  
Experimental Methods 
Materials. All reagents were used as received without further purification. Cu-BTC was obtained from 
Sigma-Aldrich as Basolite® C300. Thiols used in this work include L-cysteine (Alfa Aesar), cysteamine 
(Fluka), and D,L-homocysteine (Sigma-Aldrich). The nitrosating agent t-butyl nitrite (90%) was obtained 
from Sigma-Aldrich. Cupric chloride (CuCl2 · 2H2O) and reagent alcohol used in this work were obtained 
from EMD chemicals. Tecoflex SG80A polyurethane was obtained from Lubrizol. Compressed gas 
cylinders of O2 and ultrapure N2 (99.99%) were supplied by Airgas. Millipore purified water (18 MΩ) 
was used in the preparation of all S-nitrosothiol and CuCl2·2H2O stock solutions.  
Preparation of S-nitrosothiols. RSNOs were prepared in situ by adding 5x10-5 moles of the appropriate 
thiol to 1mL of Millipore water followed by addition of excess (1x10-4 mol) nitrosating agent, t-butyl 
nitrite. For each of the thiols investigated, the reaction solution was covered and protected from light with 
an aluminum foil wrapper and placed in an ice bath at 0 °C. After 15 min, the reaction solution was 
purged with N2 under vacuum for 5 min to remove unreacted t-butyl nitrite. Complete removal of t-butyl 
nitrite was verified by UV-Vis spectroscopy following the disappearance of the characteristic 6 point 
absorbance features between 330-410 nm. The concentrations of the RSNO solutions were monitored by 
UV-Vis spectroscopy following the absorbance band at 545 nm , Thiol: λ(nm), (ε(M-1 cm-1));  S-
nitrosocysteine (CysNO): 545, (14.5); S-nitrosocysteamine (CysamNO): 545, (14.5)); S-
nitrosohomocysteine (HcysNO): 545, (16.5). The extent of nitrosation was determined by the 




by UV-vis was compared to the total amount of thiol in solution. Results from thiol quantification 
determined the total percent nitrosation for each of the substrates to be 91 ± 2%.  
Quantification of NO. Direct NO measurements were made using chemiluminescent detection with a GE 
280i Nitric Oxide Analyzer (NOA). The solvent ethanol was added in 2 mL quantities to a specialized 
reaction vessel and was deoxygenated with a flow of N2 gas set to 200 mL/min with a simultaneous 
sampling rate of 200 mL/min under vacuum into the NOA reaction chamber. In reactions requiring a 
catalyst, the catalyst was added prior to the addition of RSNO. The MOF catalyst, Cu-BTC as either the 
free powder or the polymeric tubing was added directly to the NOA reaction vessel. Using an analytical 
balance, accurate to the one ten thousandth of a gram, 0.1 mg samples of Cu-BTC were massed to give a 
total copper content of 0.5 µmol Cu2+ in the sample. With a composition of 1.5% by weight of the Cu-
BTC in the polymeric matrix 0.0067g of tubing were used for each experiment, in order to maintain the 
same amount of Cu-BTC for the reaction.  In reactions utilizing solvated Cu2+ ion as the catalyst, a 10 µL 
aliquot of CuCl2·2H2O was injected from a 0.05 M stock solution directly into the ethanol reaction 
solution. The reaction vessel was protected from light with aluminum foil wrapping and exposed to 
ambient temperature at 22 °C. An aliquot containing 1 µmol RSNO (2x10-5 L stock solution) was 
introduced to the reaction flask via a side injection port. The resulting NO product was collected at one 
second intervals and processed using Microsoft Excel 2010. All experiments were performed in triplicate 
and the average and standard deviation reported for the total NO recovered (mol) and the half-lives (s). 
Preparation of Cu-BTC polymer composite materials. The preparation of the Cu-BTC-tubing materials 
was achieved by current industrial extrusion processing methods. The MOF was compounded into the 
polymer using a co-rotating twin screw extruder. The material was then pelletized and vacuum dried for 4 
hours at 65°C under high vacuum. The compounded polymer was then extruded into a single lumen tube 
using a 1.5” single screw extruder running at a temperature of approximately 175°C. The tubing was 
water cooled, cut to length, and vacuum dried for 4 hours at 65°C under high vacuum before storage.   
"#!
CuBTC-Poly Material SEM-EDX analysis. Using a JEOL JSM-6500F SEM with an accelerating voltage 
of 20,000 kV and a beam current of 7nA. A cross section of the Cu-BTC tubing was sputtered with 10 nm 
coating of gold. Images were taken at a 500x magnification and processed for copper content using 
adjunct EDX spectroscopy. Component mapping was evaluated between 4.5 keV and evaluated as 
generated auto phases. All data was recorded and processed using Thermo NSS Release candidate 7 
software.      
XRD measurements. Powder x-ray diffraction (pXRD) measurements were collected using a ScintagX2 
pXRD equipped with a Cu K! ("=1.5406 Å) radiation source. Scans were taken at a speed of 3°/min and 
a step size of 0.02°. Data was plotted as intensity vs 2 theta in Sci Davis scientific data analysis software. 
Results and Discussion  
MOF Extrusion into Polymeric Materials. Composite MOF polymeric materials can be prepared by 
blending the MOF particles directly into a solution of solvated polymer. In scheme 1, Cu-BTC is 
incorporated at 1.5% by weight into a solution of solvated biomedical grade polymer SG-80A. The MOF-
polymer composite materials are prepared through a two-step extrusion process. In the first step, the Cu-
BTC particles are blended at 1.5wt% with the solvated polymer. Using a twin screw extruded composite 
material is formed into pellets and dried under vacuum. The resulting pellets are then extruded once more 
and formed into single lumen tubing with a diameter of 1.5 mm. The resulting tubing used for analysis in 
the remainder of this manuscript has a rich blue coloration as a result of the incorporation of Cu-BTC into 






MOF Structural Robustness after Material Processing. The structural integrity of the composite tubing 
was assessed based on comparing the powder X-ray diffraction patterns with unmodified Cu-BTC 
crystals.  Direct comparison of the powder pattern for the initial Cu-BTC and the polymer incorporated 
Cu-BTC is shown in Figure 1. The observed reflections at 6, 7, 9, 12, 14, and 18 degrees for each of the 
samples are characteristic of Cu-BTC. The large hump shown in the Cu-BTC polymer case (Figure 1) is a 
result of the polymer matrix and is not indicative of structural deviations in the MOF structure. The 
similarities in the two diffraction patterns between the incorporated Cu-BTC and the free particles 
indicate that the MOF remains structurally robust following processing into the polymeric material.   
This is a significant finding given that over the last two decades countless reports of MOF structures have 
emerged, yet we have failed to capitalize on their potential for application.  Propositions from gas 
storage,8,9 drug delivery agents,10-13 chromatographic separations,14,15 and catalysis11,16-18 applications have 
been the forerunners, but have failed to achieve true applicability. Incorporation of MOFs into biomedical 
polymers facilitates a new area of application for these types of materials. The proposed use of MOFs in 
this work facilitates the simultaneous application of MOFs as catalysts and drug delivery agents into one 
functional material. A new avenue of exploration for MOFs is in the field of biomedicine through their 
incorporation into existing medical devices. The extrusion of polymeric materials into desired shapes and 






Figure 1. Powder X-ray diffraction pattern of polymer incorporated Cu-BTC – polymer composite (top) 
and the unmodified Cu-BTC powder (bottom).  
Imaging of Cu-BTC Incorporated into a Polymeric Material. Even dispersion of CuBTC particles 
throughout the polymeric matrix is crucial for the consistent function of the device. Visual inspection 
with the naked eye reveals a uniform blue coloration throughout the entirety of the material, which is 
indicative of CuBTC particles. Upon closer inspection of the CuBTC-poly materials using SEM imaging 
(500x) of the material surface shown in Figure 2a, the majority of the MOF crystals remain embedded 
within the polymeric matrix. The relative dispersion of the embedded Cu-BTC particles underneath the 
polymer surface layer was determined by SEM-EDX analysis using copper as a probe molecule. In Figure 
2b, the EDX phase representing the copper content and location is overlaid on the SEM image of the Cu-
BTC-polymer tubing. From this experiment, the copper content of the material appears to be evenly 
dispersed. Although, depth profiling through the interior of the material is not accessible based on the 1 
micron probing depth limitations of EDX. A large density of copper is detected on the surface particles 
attributed to the MOF crystals and is randomly dispersed over the entire area of the analyzed material. 
The copper content of the material was found to account for 4.2% of the total elemental composition of 
the Cu-BTC polymer material. The molecular formula of Cu-BTC is actually Cu3(BTC)2, indicating that 
"#!
for every one mole of MOF, there are 3 mol of copper present and, based on the initial incorporation of 
Cu-BTC at 1.5%, the theoretical amount of copper contained within the material based on the initial 
incorporation of Cu-BTC is equal to approximately 4.5%.  As such, the observed copper content observed 
for the material correlates with an even dispersion particles throughout the material.  
 
Figure 2. a) Representative SEM image of extruded Cu-BTC tubing (500x magnification). b) 
Representative SEM-EDX image of extruded Cu-BTC tubing including the overlaid elemental map  
where copper is indicated  in gold.  
Reactivity of Cu-BTC towards bioavailable RSNOs. Biologically occurring variants of RSNOs exist as a 
part of protein side chains and as small molecules.19 Small molecule RSNOs such as S-nitrosocysteine 
(CysNO), S-nitrosocysteamine (CysamNO), and S-nitrosohomocysteine (HcysNO), shown in Figure 3, 
are responsible for the safe storage and transport of NO across cell membranes and through the blood 
stream. The degradation of RSNOs resulting in the generation of NO is well known to be catalyzed by 
Cu2+ ions and more recently by Cu-MOFs.  Investigating structurally distinct RSNO species we can 
evaluate the role of substrate structure on the amount of NO generated using the extruded Cu-BTC 







The decomposition of RSNOs in the presence of the extruded Cu-BTC polymer tubing was evaluated by 
monitoring the formation of the product NO (equation 1). Chemiluminescence is an ideal technique for 
measuring NO generation based on the selectivity for NO over other interfering NOx species and the real-
time sampling capabilities.20 However, due to the fast reactivity of NO with O2 in order to ascertain that 
an accurate measurement of the generated NO was accounted for, the reaction set-up required a closed 
system that was continuously deoxygenated using N2 as a purge gas. The substitution of the reaction 
medium with ethanol in place of an aqueous solution was necessary due to the characteristic degradation 
of Cu-BTC in aqueous environments. As such this work demonstrates a proof of concept that MOF 
catalyst once incorporated into a polymeric membrane retains its capacity for  facilitating the 
decomposition of bioavailable RSNOs resulting in the generation of NO. Therefore, by substituting the 
reaction medium we are able to ascertain that the reactivity observed is a result of the intact Cu-BTC 
particles and not free Cu2+ ions that have leached into solution. The investigation of MOF catalyst that is 
stable under truly physiological conditions is ongoing.    
 
The reaction of the Cu-BTC polymer material with CysNO, CysamNO, or HcysNO resulted in the 
generation of NO, shown in Figure 4a. After a two hour reaction period with the Cu-BTC polymeric 
material the release of NO from CysNO and CysamNO stopped resulting in the generation of 75% of the 
theoretical NO. In contrast, after two hours the total amount of NO released from HcysNO was less than 
10% of the theoretical amount of NO, however NO release is observed to continue over a 15 hour period. 
The generation of NO from CysNO and CysamNO started with an induction period that lasted 45 and 90 
minutes, respectively. After the induction periods, a rapid release of NO was observed with the reactions 
proceeding to completion within a 1 hour time period. In order to determine if this observed induction 
period is a result of the polymeric material or the MOF we compared NO release with free Cu-BTC 




In Figure 4b, the generation of NO from CysNO, CysamNO, and HcysNO with the free Cu-BTC particles 
is shown. The reaction of CysamNO with Cu-BTC particles is the fastest reaching completion in 90 
minutes and lacked an induction period. In contrast the induction period persisted over the initial 90 
minute period for the Cu-BTC polymer material. The generation of NO from CysNO with the free 
particles was considerably slower with only 20% of the NO generated in the first 2 hours and lacked an 
induction period. The behavior of HcysNO with the free Cu-BTC particles corresponded to the 
encapsulated material with less than 10% of the total NO generated after 2 hours, yet still continued to 
produce NO for the next 15 hours.  
 
Figure 4. Representative NO release based on the percentage of theoretical NO recovered from CysNO, 
CysamNO, and HcysNO using a) extruded Cu-BTC polymer and b) Free Cu-BTC particles.   
The variation in reactivity between the Cu-BTC tubing and the free particles is attributed to the presence 
of a polymeric barrier and the dispersion of the particles within the reaction medium. Embedding the Cu-
BTC particles within the polymer matrix creates a barrier between the RSNO substrate and the active site 
Cu2+ sites contained within Cu-BTC, thus suggesting a diffusion mediated process that dictates the rates 




particles suggests that the larger size of HcysNO restricts accessibility of the RSNO substrate to the active 
sites of the metal centers. As a result this diffusion driven process likely accounts for the induction period 
observed for CysNO and CysamNO. The faster reactivity of CysNO with the Cu-BTC polymer material 
compared to the free particles can be correlated to the requirement that once through the polymeric barrier 
it facilitates a close interaction between the Cu-BTC particles and the substrate. Furthermore, the 
dispersion of the Cu-BTC particles in the polymer increases the accessibility of the active sites, compared 
to the free particles where considerable aggregation of the particles is observed.  
The resulting NO generated when the Cu-BTC catalyst is used is dependent on the substrate. Similar 
behavior has been noted previously for the reaction of RSNOs with solvated Cu2+ ions and is attributed to 
variations in the R substituent.21 In the case of solvated Cu2+ ions, the differences in reactivity between 
the various substrates has been attributed to the capacity for each of the substrates to form stable bidentate 
cyclic intermediates with the metal ion.22 Variations in the reactivity of RSNOs with Cu-BTC have been 
attributed to the presence of varying R groups and the resulting intermediates that are formed as a result 
of the coordination with the metal center resulting in CysamNO being more reactive towards NO 
generation than CysNO. Historically, HcysNO has been amongst the least reactive substrates as a result of 
the longer chain length and its propensity for forming an unfavorable 7 membered ring as the 
intermediate.22 In this work, the coordination environment of the active site within the MOF architecture 
only allows for the coordination of one additional ligand and as a result likely impedes the formation of a 
cyclic transition state. At this point in time, little is known about the mechanistic activity of MOF 
catalysts and is beyond the scope of this paper. However, in regards to this reaction we have identified 
two potential reaction pathways that warrant further investigation. In the first we propose the possibility 
of a redox driven mechanism which is similar to that observed for the free ion. However, the feasibility of 
a MOF catalyst undergoing redox changes at the metal center without incurring structural damage is a 
major point of concern. Alternatively, we propose a Lewis acid driven mechanism of which Cu-BTC has 




shown to generate NO as a result of reactions with Lewis acids.24 Exploration of the mechanistic avenues 
of reaction of RSNOs with Cu-MOFs will be the subject of future work.   
Conclusion  
The development of integrative materials is key for chronic medical device applications.  This requires 
materials to have sustained biological activity for prolonged periods which has not been achieved through 
current approaches. Towards sustained release materials, this work demonstrates for the first time the 
development of a biomedical device, using a common manufacturing technique, with the capacity to 
generate NO from bioavailable sources. The MOF catalyst, Cu-BTC, upon interaction with the RSNO 
substrates, CysNO, CysamNO, and HcysNO, effectively produces NO. The rates of NO release from each 
of the substrates with the MOF catalyst varied based on the substitution of the R groups. Furthermore, the 
inherent structural robustness of the MOF catalyst facilitated its incorporation into a polymeric medical 
device tubing using a common commercial manufacturing technique and an even dispersion of the 
embedded particles. This work highlights the feasibility of incorporating embedded catalysts into bulk 
materials to produce NO utilizing external sources.  Furthermore, the ability to tune the NO release 
function using a single catalyst in polymer tubing based on the NO donor it is exposed to is a promising 
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In order to expand the scope of applicability of MOFs, there is increasing interest in the process ability of 
MOFs into composite materials.1,2 The preparation of MOF composite materials can be achieved either 
through the incorporation of MOF particles as blends into the matrix of polymeric materials or by in situ 
growth onto the surface of rigid substrates, to form what are known as SURMOFs.3,4, Advantageously, 
SURMOFs offer the capacity for functionalizing materials with uniform coatings of MOF thin films, with 
control over the thickness of the deposited layer, orientation of the crystal face, and even patterned 
surface deposition.5,6 The growth of SURMOFs however is primarily limited to the growth on rigid 
inorganic substrates with only few reports of growth on organic substrates despite significant advantages 
towards the development of functional materials. 
In this work, the surface functionalization of the flexible polymeric substrate Cellulose was adhered with 
CuBTC particles grown via epitaxial layer by layer growth under ambient conditions. The resulting 
CuBTC –Cellulose swatches were characterized for the formation of CuBTC particles by pXRD and 
ATR-IR spectroscopy. SEM imaging was used to evaluate the surface coverage and the uniformity of the 
crystals. Furthermore, the CuBTC-cellulose swatch is explored as a heterogeneous catalyst for the 
generation of the bioactive agent nitric oxide. This work highlights the feasibility of developing numerous 
MOF composite materials at polymer interfaces towards application for a wide range of polymeric 






The goal for the preparation of MOF biomaterials is to mediate interfacial responses between the foreign 
object and the host environment. As such the most crucial location for the placement of MOF materials is 
directly onto the device surface rather than as a blend where the majority of the included MOF is below 
the material surface. To this effect the uniform deposition of MOFs onto functionalized surfaces has been 
shown using in situ synthetic growth methods.7, Biomaterials are fabricated to take on various shapes and 
sizes in order to accommodate numerous functionalities. As such a synthetic method which can 
accommodate a wide range of substrates that is indifferent to size, topology, and even varied topographies 
would be advantageous for the preparation of MOF coated biomaterials.8  
For the synthesis of surface grown MOFs (SURMOFs) it is essential that the growth substrate remains 
intact over the course of MOF synthesis. As such many reports for the growth of SURMOFs are for 
robust inorganic substrates, gold, silica, or alumina.6,9,10,11 However, with the emerging interest of MOFs 
in sensing, chromatographic, filtration, and even protective textiles it is essential to expand the capacity 
for the growth of SURMOFs on flexible organic substrates.12 The critical requirement for the attachment 
of the MOF to a polymer surface is tuning of the surface functionality such that it corresponds with the 
coordinating ligand of the MOF. Towards this end, there are few reports of the successful in situ growth 
of MOFs on polymeric substrate using microwave assisted, slow diffusion reactions, and layer by layer 
(LbL) epitaxial growth methods.13,14,15,16,  There is particular interest in the use of the LbL method due to 
its effectiveness under mild reaction conditions at room temperature in aqueous solvents compared to 
solvothermal methods.17,5  The layer by layer method relies on alternating between metal ion and ligand 
precursor solutions, with the number of cycles directly corresponds the film thickness. Therefore, using 
the LbL approach we propose the growth of SURMOFs on flexible organic substrates that is impartial to 




Presented herein is the rapid growth of the archetypal MOF, CuBTC directly onto the surface of the 
flexible polymeric substrate, Cellulose, using room temperature epitaxial LbL deposition. CuBTC is 
assembled into a permanently porous crystalline network of Cu2+ metal ions coordinated to the carboxyl 
functionalities of 1,3,5-benzenetricarboxylic acid, as such it is essential that the surface of the polymer be 
derivatized to include carboxyl pendant groups through carboxymethylation of polymeric hydroxyl 
groups. Subsequently, CuBTC particles were synthesized directly on the polymeric surface by 
incorporating the swatches of the carboxymethylated cellulose into a saturated solution of Cu(II)Acetate 
in water for 5 minutes followed by immersion of the swatch in the ligand solution of 0.2M 1,3,5-
Benzenetricarboxylate for an additional 5 minutes. This process was repeated for a total of 8 cycles. The 
characterization of the resulting CuBTC-Cellulose swatches was evaluated visually for MOF surface 
coverage and uniformity by SEM imaging; structurally by pXRD and ATR-IR spectroscopy; and for 
fixation to the substrate through leaching studies.  Furthermore, we explored the utility of the CuBTC-
cellulose swatch as a heterogeneous catalyst for the generation of the bioactive agent nitric oxide.  
Experimental Methods 
Materials. The natural cotton fabric (TIC/400) was obtained from SDL Atlas and used as received.  
Reagents used in this work include, copper (II) acetate (Cu(OAc)2●H2O) (Sigma Aldrich), 1,3,5-
benzentricarboxylic acid (H3BTC) (Acros Organics) and sodium chloroacetate (C2H2ClNaO2) (Alfa 
Aesar). Dimethylformamide (DMF), reagent alcohol and sodium hydroxide were all obtained from 
Fischer Scientific. All reagents were used as received without any further purification. 
Carboxymethylation of Cellulose fabric. In order to obtain an anchoring point for the deposition of Cu-
BTC onto the cellulose matrix, the cellulose fabric was carboxymethylated using sodium hydroxide as the 
catalyst, shown in Scheme 1.  A 1M solution of sodium chloroacetate (1.16 g) and 5% NaOH (2.5 mL) 
was prepared by dissolving in a total volume of 10 ml, followed by the cellulose being allowed to react 




Surface Deposition of Cu-BTC. Copper Acetate (1.078 g) was mixed in 15 mL of millipore water (18 
MΩ) and allowed to completely dissolve to create a 0.36 mM solution. H3BTC (631 g) was dissolved in 
15 mL of a 1:1:1 ratio DMF:ethanol:water to obtain a 0.2 M solution.  Cotton samples were sequentially 
dipped in the copper acetate (Cu(OAc)2*2H2O) solution, followed by the H3BTC solution, 5 min each, for 
a total of 8 alternating cycles.  After each dipping the cotton fabric was rinsed thoroughly with millipore 
water to remove any excess reagents. After 8 cycles, the samples were washed for 5 hours each, in 
ethanol followed by DMF to remove any Cu-BTC which was not covalently bonded to the cellulose. 
Material Imaging: Using a JEOL JSM-6500F (FSEM) with an accelerating voltage of 3.0 kV and a 
working distance of 4.0 mm. Images were taken at magnification values of 500x, 2,000x and 9,000x and 
processed for copper distribution using EDX spectroscopy. The EDX spectrum was collected at an 
accelerating voltage of 5 kV   at 130X magnification. All data was processed using Thermo NSS Release 
candidate 7 software.  
XRD measurements. Powder X-ray diffraction (pXRD) measurements were carried out using a Scintag 
X2 pXRD with CuKα radiation.  
Results and Discussion 
Carboxymethylation of Cellulose to include anchor sites. As shown in Scheme 1, the hydroxyl groups 
incorporated onto the polymeric backbone of cellulose were derivatized with chloroacetate to form 
pendant carboxylic acid groups on the polymeric surface. Carboxymethylation of the cellulose was 
evaluated my comparing the infrared spectrum of parent cellulose and the reacted material, shown in 
Figure 2. The appearance of the adsorption peak at 1590 cm-1 for the reacted particles is indicative of a 
C=O stretch corresponding to the incorporation of carboxyl functionalities.16 The successful modification 
of the cellulose with carboxyl groups provides the necessary surface composition for the attachment and 
subsequent growth of MOFs on the material surface.  





Surface Growth of CuBTC. Next in situ growth of Cu-BTC onto the carboxylated polymers through LBL 
synthesis, under ambient conditions, where the polymer undergoes alternative immersion in solutions of 
Cu(OAc)2*H2O and the ligand H3BTC for 5 minutes periods constituting a cycle, is shown in Scheme 2. 
The process was repeated for a total of 8 cycles, with each cycle beginning with immersion in the copper 
solution, since the coordination environment of the metal ion creates an anchor point for the attachment of 
the particles to the surface. Furthermore, the coordination cluster serves as a platform for the growth of 
CuBTC particles, where each subsequent immersion cycle facilitates the stepwise growth of CuBTC onto 
the material surface and the resulting thickness of the surface grown crystal layer is well known to be 
directly correlated with number of repeated cycles. With each cycle the polymeric material gradually up 
took a turquoise coloration, which even after thorough washing and leaching studies was determined to be 
adhered to the surface and subsequent desolvation of the material resulted in the transformation to a royal 
blue coloration. These results are consistent with the well-defined behavior of solvated versus desolvated 
CuBTC particles. To further confirm the synthesis of surface adhered CuBTC particles, we assessed 
structural properties through attenuated total reflectance infrared spectroscopy (ATR-IR) and powder X-









Scheme 2. Layer by layer growth of CuBTC onto carboxymethylated cellulose substrates 
 
Characterization of CuBTC-Cellulose swatch. The formation of CuBTC onto the polymeric surface was 
evaluated based on a comparison of the crystalline signature of the material with traditionally prepared 
CuBTC particles using pXRD. As shown in Figure 1, the diffraction pattern of CuBTC-Cellulose 
corresponds with the diffraction pattern for the free particles. However, in the case of CuBTC-cellulose 
material there are additionally diffraction peaks present at 15 degrees and 23 degrees, which are artifacts 
of diffraction associated with the polymeric surface, shown in Figure 1. Overall, the presence of the 
matching diffraction peaks signifies the successful deposition of a crystalline material, not just an 
amorphous salt. Subsequently, we investigated the structural identity of the crystals by ATR-IR 
spectroscopy. The resulting IR spectra of CuBTC cellulose material, shown in Figure 1, corresponds with 
CuBTC particles. Notably, the spectral properties associated with the polymeric substrate are not evident, 






Figure 1.  (left) pXRD diffraction patterns  of a) CuBTC powder b) composite material  c) cellulose 
diffraction patterns. (right) and ATR-IR spectra of a) CuBTC powder b) composite material c) 
carboxymethylated cellulose d) cellulose. 
SEM Imaging and Leaching Studies. We visually inspected the formation of MOF particles on the surface 
of the polymeric substrate by SEM at 500x and 5000x magnification, shown in Figure 2. At 500x 
magnification we observe the fibrous strands of cellulose are deposited with the CuBTC crystals with 
excellent surface coverage over the entire surface. Upon closer inspection of the CuBTC partcles we 
observe that well defined octahedral crystals with an average particle size of 10.55 ± 4.01 µM are formed 
across the curved surface of the fiber. The adhesion of the particles to the surface was subsequently 
evaluated by leaching studies where CuBTC Cellulose swatches were immersed in ethanol over a one 
week period. In Figure 3 the resulting weight percentage of the material is presented for swatches which 
were immersed continuously in the soak solution. Following removal of the swatch from the soak 
solution the material was dried and weighed and the soak solution was evaluated for copper content by 
elemental analysis. After a 1 week period the swatches retained in ≥95% of the initial weight and 
elemental analysis of the solution indicated the solution copper content was <1% of the total Cu content 
"#!
of polymer bound CuBTC particles. Taken together these results indicate that the deposited CuBTC 
particles are anchored to the surface of the polymeric cellulose substrates. 
Figure 2. SEM images of CuBTC-Cellulose swatches at 500x (left) and 5,000x (right) magnification after 
leaching analysis studies. 
Figure 3. Leaching studies for CuBTC . Elemental analysis studies indicated no detectable Cu in solution 
over the 1 week period.  
We have demonstrated the development of a synthetic method for the functionalization of preformed 




CuBTC crystals under ambient conditions. Notably the fibrous polymeric network associated with 
Cellulose is composed of a weave type configuration which does not compromise the surface coverage of 
the materials nor does it impact the uniformity in crystalline deposition on the material surface. Based on 
this exceptional demonstration for the formation of a MOF composite material the next logical step is to 
apply the material in an application based setting. The use of fibrous materials are often found in the 
development of protective textiles including bandages and through the incorporation of MOFs, the 
materials can be tuned to mediate interfacial responses between damaged tissues and the bandage for 
minimizing the risk of infection and promoting wound healing responses.18  As an essential bioagent for 
mediating proliferative cellular effects and immune responses, nitric oxide, is a target therapeutic to 
investigate for wound healing applications.19 Towards this end we have explored the functionality of the 
CuBTC-Cellulose swatch for the catalytic generation of nitric oxide from bioavailable substrates, S-
nitrosothiols. 
Heterogeneous Catalysis Mediated by CuBTC-Cellulose Swatches. The reactivity of CuBTC-Cellulose  
swatches as heterogeneous catalysts for the generation of NO from select bioavailable NO donors shown 
in Figure 4, S-nitrosocysteine (CysNO), S-nitrosocysteamine (CysamnNO), and S-nitrosohomocysteine 
(HCysNO) were evaluated by monitoring the formation of the product NO via chemiluminescence 
detection. The resulting rate of NO generation from each RSNO increased in order of 
HCysNO>CysNO>>CysamNO as shown in Table 1. These results concur with the previous findings 
utilizing the unsupported CuBTC particles (ref Ch 3). As shown in Table 1, the reactivity of the CuBTC 
swatches towards NO generation is analogous to that of the free particles.  
 








Subsequently, the CuBTC swatch was confirmed as the catalyst responsible for the generation of NO and 
not the leached copper ions or unadhered CuBTC particles. Towards this end, in a classical evaluation for 
a heterogeneous catalyst the swatch was removed from solution during the reaction and the resulting NO 
release following removal was examined. Since NO release measurements are recorded in real time we 
are able to determine the instantaneous effects of the removal of the catalyst from solution. As shown in 
Figure R, removal of the swatch immediately halted the generation of NO and returned the levels of NO 
generation to a baseline reading observed in the absence of the catalyst. Subsequently, reintroduction of 
the CuBTC swatch resulted in the return of catalyzed NO generation. Based on these experiments we are 
confident that the catalyzed generation of NO is a result of the covalently bound CuBTC particles present 
on the CuBTC swatch is responsible for the observed catalytic activity and not Cu2+ ions leached into 
solution.    
 
Donor Blank (nM s-1) Swatch (nM s-1) Neat (nM s-1) Cu2+   (nM s-1) 
CysNO 2.05 ± 0.88 7.46 ± 0.83 9.64 ± 0.26 161 ± 18 
CysamNO 2.11 ± 0.29 20.3 ± 0.63 21.3 ± 0.82 231 ± 13 




Figure 5. Real time NO release curve of CysamNO as the substrate in the presence of CuBTC-Cellulose 
swatch. Where removal of the swatch results in a return to baseline of the NO generation.  
 
Conclusion  
In summary we present the first instance of in situ growth a MOF onto a preformed polymeric substrate. 
Utilizing a layer by layer approach CuBTC crystals were deposited onto carboxymethylated cellulose 
under ambient conditions. Notably, excellent surface coverage with well-defined CuBTC crystals was 
evident on the uneven surface associated with the fibrous composition of the cellulose. This work 
highlights the feasibility of developing numerous MOF composite materials at polymer interfaces towards 
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The primary goal of the research contained within this dissertation is to develop a therapeutic material 
which generates the bioactive agent nitric oxide from an endogenous source. Nitric oxide (NO) is a 
bioactive agent generated by most nucleated cells in the human body known to mediate antimicrobial 
effects and promote the proliferation of healthy tissues.1 Therefore, the development of an NO releasing 
material which can sustain the generation of physiologically relevant levels of NO by relying on 
endogenous supplies of NO over the device lifetime will result in the development of an antifouling 
material surface with potentially regenerative effects. Achieving this goal requires the separation into 
three parts: First the development of a measurement method to quantify NO; second identification of 
catalytic material which not only catalyzes the generation of NO from bioavailable substrates but also 
remains structurally intact in the physiological environment. Lastly, the NO catalyst must be incorporated 
into a polymeric secondary support for use in biomedical devices.     
The development of any material requires a means to evaluate its effectiveness. Therefore, in order to 
evaluate any NO materials that may be prepared a method for the accurate quantification of generated NO 
must first be developed. In this work chemiluminescence based NO detection was established as reliable 
method for the accurate quantification of NO generated from small molecule donors in cell media 
solution.2 Riboflavin was identified as a NO scavenging agent included in cell media solutions as a 
vitamin additive. Variations in the concentration of riboflavin and the rate of NO release from the NO 
donors was found to influence the amount of NO scavenged from solution. Based on these results many 
discrepancies in the literature regarding the therapeutic range of NO can be rectified by taking into 
account the NO scavenging capacity of the media solutions.  
"#$!
 The development of an NO catalyst for the sustained generation of NO from bioavailable S-nitrosothiol 
(RSNO) substrates requires accessible Cu2+ catalytic sites and structural integrity in the physiological 
environment, shown in Figure 1.3 The use of a solid state catalyst is advantageous based on the ease of 
incorporation into secondary supports and the inherent robustness of the material.  In particular metal 
organic frameworks are regularly explored as both drug delivery vehicles and heterogenous catalysts 
making them attractive targets for use as NO catalysts. The variable chemical and physical properties of 
MOFs make them promising platforms for biomedical applications due to their potential design for 
biodegradability and chemical and structural tunability. 
Figure 1. Illustration of RSNO decomposition to produce NO via a MOF catalyst with coordinatively 
unsaturated Cu2+ metal centers  
Initial exploration of MOFs as NO catalysts in this work focused on the use of the classic and 
commercially available MOF, CuBTC. The use of CuBTC demonstrated proof of principle that Cu-MOFs 
can drive the catalytic generation of NO from RSNO’s, where the rate of NO generation from structurally 
distinct RSNOs (Table 1) was dependent on substrate size and polarity of the functional groups. The 




solvated Cu2+ ions and the blank is shown in Table 1. The limitation of CuBTC as a NO catalyst for 
biological applications was the limited moisture stability of the framework, which necessitated that all 
catalytic activity be evaluated in a non aqueous solvent (ethanol).  
Table 2. Rate of NO Generation from various RSNOs 
RSNO Blank (nM s-1) CuBTC (nM s-1) CuCl2 (nM s-1)  
CysNO 2.55 ± 0.21 10.4 ± 0.2 161 ± 18 
CysamNO 2.23 ± 0.30 21.3 ± 0.9 231 ± 12 
HcysNO 3.22 ± 0.19 3.10 ± 0.94 157 ± 12 
MPANO 2.80 ± 0.11 4.56 ± 0.68 214 ± 19 
MeNO 1.60 ± 0.27 11.1 ± 1.6 264 ± 23 
TGANO 2.30 ± 0.60 20.1 ± 1.1 515 ± 73 
TLANO 1.23 ± 0.10 26.1 ± 1.7 441 ± 45 
All rates are reported at 25 °C.  Data points were run in triplicate and reported to the 95% confidence 
interval.  
Encouraged by the success of CuBTC as a MOF NO catalyst, alternative MOFs with increasing stability 
in aqueous solutions were sought. Substitution of the carboxyl ligand (1,3,5-benzetricarboxylic acid) 
contained with CuBTC  for a triazolate analogue (1,3,5-benzenetristriazole) results in the formation of a 
robust water stable MOF with coordinatively unsaturated Cu2+ metal centers, CuBTTri.4 Investigation of 
CuBTTri structural stability in aqueous mediums routinely used for in vitro and in vivo experiments, 
including phosphate buffered saline (PBS), cell media, and whole blood by assessing the resultant 
crystallinity of the material by pXRD revealed the material remains intact, shown in Figure 2. 
Subsequently, the reaction of CuBTTri with an RSNO substrates resulted in the catalytic generation of 
NO with kinetic control imparted as a function of catalyst loading. While rigorous in vitro and in vivo 
testing remains to be done to examine the full extent of the potential of CuBTTri in a therapeutic setting, 
this is the first report of a MOF which can catalytically generate a bioactive molecule from an 
endogenous source on the surface of a polymeric film with the capacity for tunable release kinetics in 





Figure 2. pXRD patterns of CuBTTri particles as the initial unreacted particles and following immersion 
in phosphate buffered saline, cell media, and fresh whole blood.  
Finally the feasibility of developing composite MOF-polymer biomedical devices was investigated. The 
development of MOF composite materials can proceed by either embedding preformed MOF particles 
within the polymeric matrix prior to manufacturing of the device or MOFs can be grown in situ as thin 
films directly onto the surface of a preformed substrate. In this account both approaches to MOF 
composite material preparations were pursued.  The preparation of blended composites was demonstrated 
via processing into single lumen tubing via a commercial extrusion process.5 Evaluation of the processed 
material indicated that the structural integrity of the MOF was preserved as well as the reactivity as an 
NO catalyst.  
Use of the blended approach is favorable when the material comes direct from a manufacturer, however 
in many cases the preparation of a composite MOF material with already prepared substrates is more 




flexible organic polymers used for the construction of many biomedical devices.  As a result this work 
demonstrated room temperature epitaxial growth of CuBTC particles onto the surface of the natural 
organic polymer cellulose (cotton fabric). The deposited MOF crystals confirmed by pXRD as CuBTC 
crystals and were determined to be adhered to the material surface after vigorous washing and leaching 
studies. In Figure 4, SEM imaging of the material indicated that the crystals exhibited excellent surface 
coverage across the uneven cellulose fabric strands with well-defined 10µM MOF crystals. Evaluation of 
the CuBTC-cellulose swatches indicated that the material catalyzed the generation of NO at rates 
comparable to unsupported CuBTC particles. Subsequent removal of the CuBTC-cellulose material halted 
the reaction progress, confirming its presence as a heterogeneous catalyst.  
    
Figure 4. SEM images of CuBTC-Cellulose swatches at 500x (left) and 5,000x (right) magnification after 
leaching analysis studies. 
The research presented in this dissertation was undertaken with the intention of making a significant 
contribution to the field. In order to fulfil the stated goal of developing a catalytic NO material for the 
long term applications in biomaterials it was necessary to start from the ground up requiring the 
development of a measurement method for assessing the materials, identification of a suitable catalytic 
material, and ultimately processing into usable devices. In light of the success of this work it is important 




will likely explore the development BioMOFs aimed at mimicking enzymatic process or perhaps even as 
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Appendix(1(
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(
Table(S1.(Summary(of(Cell(Media(Components(
! EC*!
(mM)!
NB**!
(mM)!
Amino(Acids( ! !
Glycine! 0.0307! 0.4!
L9Alanine! 0.0303! 0.0225!
L9Arginine!hydrochloride! 0.3! 0.398!
L9Asparagine9H2O! 0.1! 0.00553!
L9Aspartic!acid! 0.1! 0!
L9Cysteine!2HCl.!H2O! 0.199! 0.26!
L9Glutamic!Acid! 0.0299! 0!
L9Histidine!hydrochloride9H2O! 0.2! 0.2!
L9Isoleucine! 0.504! 0.802!
L9Leucine! 1! 0.802!
L9Lysine!hydrochloride! 0.995! 0.798!
L9Methionine! 0.101! 0.201!
L9Phenylalanine! 0.2! 0.4!
L9Proline! 0.1! 0.0675!
L9Serine! 0.305! 0.4!
L9Threonine! 0.101! 0.798!
L9Tryptophan! 0.0201! 0.0784!
L9Tyrosine! 0.1! 0.398!
L9Valine! 1! 0.803!
! ! !
Vitamins( ! !
Biotin! 2.99E905! 0!
Choline!chloride! 0.1! 0.0286!
D9Calcium!pantothenate! 0.0252! 0.00839!
Folic!Acid! 0! 0.00907!
Folinic!Acid!Calcium!salt! 0.00117! 0!
Niacinamide! 0.05! 0.0328!
Pyridoxine!hydrochloride! 0.0102! 0.0196!
Riboflavin! 1.01E905! 0.00106!
Thiamine!hydrochloride! 0.0101! 0.0119!
Vitamin!B12! 0.00001! 0.000005!
!
!
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i9Inositol! 0.04! 0.04!
! ! !
Inorganic(Salts( ! !
Ammonium!Metavanadate!NaVO3! 4.9E906! 0!
Ammonium!Molybdate!((NH4)6Mo7O249
4H2O)!
0.000003! 0!
Calcium!Chloride!(CaCl292H2O)! 1.6! 1.8!
Cupric!sulfate!(CuSO495H2O)! 4.8E906! 0!
Ferric!sulfate!(FeSO497H2O)! 0.00102! 0!
Ferric!Nitrate!(Fe(NO3)3"9H2O)! 0! 0.000248!
Magnesium!Chloride!(anhydrous)! 0! 0.814!
Magnesium!Sulfate!(MgSO497H2O)! 10.02! 0!
Manganese!Sulfate!(MnSO49H20)! 1.2E906! 0!
Nickelous!Chloride!NiCl2!6H2O! 3E907! 0!
Potassium!Chloride!(KCl)! 3.97! 5.33!
Selenious!Acid!H2SeO3! 2.95E905! 0!
Sodium!Bicarbonate!(NaHCO3)! 14! 26.19!
Sodium!Chloride!(NaCl)! 110.86! 68.97!
Sodium!Meta!Silicate!Na2SiO3!9H2O! 0.00986! 0!
Sodium!Phosphate!dibasic!(Na2HPO497H2O)! 0.5! 0.906!
Zinc!Sulfate!(ZnSO49H2O)! 0.000001! 0.000674!
! ! !
Other(Components( ! !
Adenine! 0.001! 0!
D9Glucose!(Dextrose)! 5.56! 0!
Lipoic!Acid! 1.02E905! 0!
Phenol!Red! 0.0329! 0.0736!
Putrescine!2HCl! 1.2E906! 0!
Sodium!Pyruvate! 1! 0!
Thymidine! 9.92E905! 0!
HEPES! 0! 10.92!
! ! !
*EC!9!MCDB!131,!no!Glutamine! ! !
*NB!9!NEUROBASAL™!Medium!(1X)!liquid!
!
